Singular Health Group Limited
Appendix 4E
Preliminary final report

1. Company details

Name of entity:	Singular Health Group Limited
ABN:	58 639 242 765
Reporting period:	For the year ended 30 June 2026
Previous period:	For the year ended 30 June 2025

2. Results for announcement to the market

	30 June 2026 $	30 June 2025 $	Change $	Change %
Revenues from ordinary activities	1,428,231	235,393	1,192,838	507%
Loss from ordinary activities after tax attributable to the owners of Singular Health Group Limited	(6,340,453)	(6,376,210)	35,757	(1%)
Loss for the year attributable to the owners of Singular Health Group Limited	(6,340,453)	(6,376,210)	35,757	(1%)

Dividends
There were no dividends paid, recommended or declared during the current financial period.

The profit for the Group after providing for income tax amounted to $nil (30 June 2025: loss of $6,376,210).

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	3.26	4.34

4. Control gained over entities

During the year, the following companies were formed in Delaware, United States and Singapore.

Name of entities (or group of entities)	Singular Health Group USA Pty Ltd[1] Singular Health Group USA LLC[2] SHG Health Pte Ltd[3]
Date control gained	[1]4 July 2025 [2]7 August 2025 [3] 12 June 2026

5. Dividends

Current period
There were no dividends paid, recommended or declared during the current financial period.

Previous period
There were no dividends paid, recommended or declared during the previous financial period.

6. Details of associates and joint operations entities

Name of associate	Reporting entity's percentage holding Reporting period %	 Previous period %
Singular Imaging Solutions U.S Inc	30.00%	-

On 18 August 2025, the Company was incorporated under the Laws of the State of Delaware.

The Group holds a 30% equity interest in Singular Imaging Solutions U.S Inc and accounts for the investment as an associate using the equity method. As at 30 June 2026, the carrying amount of the investment was nil as no consideration was paid and no material share of profits or losses was recognised during the period

7. Foreign entities

The Group includes operations in Singapore and United States. These entities prepare financial statements in accordance with International Financial Reporting Standard as issued by the International Accounting Standard Board. No material difference exists between these standards and Australian Accounting Standards.

8. Audit qualification or review

The financial statements have been audited and an unmodified opinion has been issued.

9. Attachments

The Annual Report of Singular Health Group Limited for the year ended 30 June 2026 is attached.

10. Signed

Signed ______________________________ Date: 28 August 2026

Denning Chong
Managing Director

Singular Health Group Limited

ABN 58 639 242 765

Annual Report - 30 June 2026

Singular Health Group Limited
Contents
30 June 2026

General information

The financial statements cover Singular Health Group Limited as a Group consisting of Singular Health Group Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Singular Health Group Limited's functional and presentation currency.

Singular Health Group Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

Registered office	**Principal place of business**
Level 5/191 St Georges Terrace Perth WA 6000	E3 and E4, 661 Newcastle Street Leederville Australia 6007

A description of the nature of the Group's operations and its principal activities are included in the Directors' report, which is not part of the financial statements.

Singular Health Group Limited
Corporate directory
30 June 2026

Directors	Howard Digby - Non-Executive Chairman Denning Chong - Managing Director Andrew Just - Non-Executive Director
Company secretary	Steven Wood
Registered office	Level 5/191 St Georges Terrace Perth WA 6000
Principal place of business	E3 and E4, 661 Newcastle Street Leederville WA 6007
Share register	Automic Registry Services Level 5, 191 St Georges Terrace Perth WA 6000 Telephone: +1300 288 664 (within Australia) +61 2 9698 5414 (outside Australia)
Auditor	Pitcher Partners BA & A Pty Ltd 12-14 The Esplanade Perth WA 6000 Phone: (08) 9322 2022
Solicitors	Squire Patton Boggs Brookfield Place, Level 11/125 St Georges Terrace, Perth WA 6000 Phone: (08) 9429 7444
Bankers	National Australia Bank Level 14, 100 St Georges Terrace, Perth, WA 6000
Stock exchange listing	Singular Health Group Limited shares are listed on the Australian Securities Exchange (ASX code: **SHG**)

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of Singular Health Group Limited (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2026 ('FY26').

1. Information on Directors

The following persons were Directors of Singular Health Group Limited during the whole of the financial year and up to the date of this report, unless otherwise stated:

Name:	**Howard Digby**
Title:	Non-Executive Chairman and Non-Executive Director
Qualifications:	BEng (Hons)
Experience and expertise:	Mr. Digby began his career at IBM and has spent 25 years managing technology related businesses across the Asia Pacific region, of which 12 years were spent in Hong Kong ending with The Economist Group as Regional Managing Director. Prior to this he held senior management roles at Adobe and Gartner where his clients included major semiconductor players inclusive of Samsung, Hynix and TSMC. Upon returning to Perth, Howard served as Executive Editor of WA Business News and now spends his time as a company director, advisor and investor, having played key roles in several M&A and reverse takeover transactions. He is currently a corporate consultant to Forrest Capital and an advisor to a number of private and start-up technology businesses.
Other current directorships:	Non-Executive Director: Elsight Limited (ASX: ELS) - appointed on 13 December 2016 Non-Executive Director: 4DS Memory Limited (ASX: 4DS) - appointed on 7 December 2015
Former directorships (last 3 years):	Non-Executive Director of Spenda Limited (ASX: SPX) - appointed on 1 August 2019 and resigned on 21 November 2024
Interests in shares:	722,275 ordinary fully paid shares
Interests in options:	1,250,000 unlisted options @$0.08 expiring 8 Dec 2027 1,000,000 unlisted options @$0.25 expiring 15 Apr 2028
Interests in rights:	Nil

Name:	**Denning Chong**
Title:	Chief Executive Officer and Managing Director
Qualifications:	LLB. Dist., B. Com
Experience and expertise:	Denning Chong has been the principal of James Chong Lawyers since 2004 having significant experience in cross border transactions, and large commercial and corporate due diligence and acquisitions. Denning is on the Board of Directors of Mutual Limited, a fund management business with over AUD$4bn under management. Denning is also a director for the Australian subsidiaries of SGX listed Hiap Hoe Limited and a director of Aloft Hotel Perth. Denning is one of the founders of Singular Health and was involved in the early-stage funding and governance of Singular Health since its incorporation.
Other current directorships:	N/A
Former directorships (last 3 years):	N/A
Interests in shares:	17,429,719 ordinary fully paid shares
Interests in options:	11,250,000 unlisted options @ $0.08 expiring 8 Dec 2027 10,000,000 unlisted options @$0.25 expiring 15 Apr 2029 6,000,000 unlisted options @$0.55 expiring 30 Nov 2029
Interests in rights:	10,000,000 performance rights expiring 30 Jun 2028

Name:	**Andrew Just**
Title:	Non-Executive Director
Qualifications:	Bec, Hec, MBA, GAICD
Experience and expertise:	Andrew Just was formerly the Regional Director Asia Pacific for Radiometer, a Danaher Company and is currently CEO of Aeris Environmental. He has 30 years' global experience in delivering growth and scale competencies with leading Fortune 500 companies, including GE Healthcare, Danaher, Stryker, and Cochlear. Andrew has held a variety of senior leadership roles across diverse business functions, with expertise in sales and marketing, performance management, commercial transactions, and operations in both turnaround and growth environments.
Other current directorships:	N/A
Former directorships (last 3 years):	N/A
Interests in shares:	336,364 ordinary fully paid shares
Interests in options:	1,000,000 unlisted options @ $0.08 expiring 8 Dec 2027 1,000,000 unlisted options @ $0.25 expiring 15 Apr 2028
Interests in rights:	Nil

The relevant interest of each director in the shares, and rights or options over such instruments issued by the companies within the Group and other related bodies corporate, as notified by the directors to the ASX in accordance with **S205G**(**1**) of the *Corporations Act 2001*, at the date of this report is disclosed above.

2. Company secretary

Steven Wood is a Principal at Automic Group, specialising in company secretarial and financial management services. Steven is a Chartered Accountant and provides company secretarial and financial management services to both ASX and unlisted public and private companies. He has been involved in various private, seed capital raisings as well as successful ASX IPO listings, and has experience in takeovers and schemes. Prior to joining Automic, Steven was a Director at Grange Consulting Group Pty Ltd for 12 years.

Mr. Wood is currently Non-executive Director for Arika Resources Limited (ASX: ARI) (previously known as Metalicity) and Company Secretary for a number of ASX listed entities including Caspin Resources Limited (ASX: CPN) and Anax Metals Limited (ASX: ANX).

3. Directors' meetings

The number of meetings of the Company's Board of Directors ('the Board') held during the year ended 30 June 2026, and the number of meetings attended by each Director were:

Director	**Board Meetings**	
	Attended	**Held**
Howard Digby	5	5
Denning Chong	5	5
Andrew Just	5	5

Held: represents the number of meetings held during the time the Director held office. The Company has not constituted separate committees at this point in time.

4. Principal activities

During the financial year the principal continuing activities of the Group consisted of development and commercialisation of the 3DICOM™ platform, enterprise healthcare imaging/interoperability solutions, education applications and associated regulatory and product-development activities

There were no significant changes in the nature of the activities of the Group during the year.

5. Financial and Operating review

The loss for the Group after providing for income tax amounted to $6,340,453 (30 June 2025: $6,376,210).

As disclosed in the financial report, the Group recorded an operating loss of continuing operation $6,340,453 (30 June 2025: $6,262,061) and a cash outflow from operating activities of $5,302,401 for the year ended 30 June 2026 (30 June 2025: $2,341,356). As at 30 June 2026, the Group had cash and cash equivalents of $2,362,017 (30 June 2025: $628,648), term deposits of $7,700,000 (30 June 2025: $13,050,000) and had a positive working capital of $10,407,131 (30 June 2025: $12,953,756).

The Group reported a loss after tax of $6,340,000 for the year ended 30 June 2026. The Group delivered strong revenue growth, with revenue increasing to $1,430,000 from $203,069 in FY2025.

Research and development grant income of $471,540 and increased interest income of $444,099 further supported total income during the year. The Group continued to invest in product development, commercialisation activities and organisational capability, resulting in higher research and development, employee and marketing expenses.

Operating expenses were partially offset by a reduction in non-cash share-based payment expense, which decreased to $2,090,000 from $3,270,000 in the prior year.

The significant increase in revenue demonstrates continued commercial progress, while the Group remains focused on expanding market adoption of its technology.

During FY26, Sthe Group continued to invest in the development and commercialisation of its 3DICOM™ platform while maintaining a disciplined approach to capital management. Investment throughout the year was directed towards product development, expansion of enterprise interoperability capabilities, regulatory compliance, commercial execution, and the organisational capability required to support the Group's growing U.S. customer base.

The Group achieved a significant increase in customer receipts during the second half of the financial year, supported by the contracted US$500,000 licence payment received from Provider Network Solutions (PNS). This represented an important milestone in the Group's transition from technology development to commercial revenue generation and validates the commercial deployment strategy being executed within the United States.

Operating expenditure remained aligned with the Group's strategic priorities, with continued investment in research and development, engineering capability, product commercialisation, customer deployments and regulatory initiatives. During the year, the Group also strengthened its product and engineering leadership, expanded enterprise workflow functionality, progressed international patent protection, and maintained compliance with key healthcare security standards, positioning the Group for future commercial growth.

The Group also strengthened its capital position through the exercise of employee and investor options during the year, generating $1,545,000 in proceeds, while maintaining prudent financial management and preserving a strong balance sheet. As of 30 June 2026, the Group held cash and cash equivalents of $10.1 million. This financial position provides the Group with a solid foundation to execute its commercial strategy, progress key U.S. opportunities and continue investing in product innovation and regulatory compliance.

Overall, the Board considers the Group's financial position to be strong and appropriate to support the continued execution of its strategic objectives as the Group advances the commercial deployment of its healthcare imaging infrastructure platform across provider, payer, education and government markets.

Review of operations

During the year ended 30 June 2026, the Group continued the transition from product development to commercial execution, achieving significant progress across healthcare deployments, enterprise partnerships, government initiatives, regulatory advancement and technology development. Throughout FY26, the Group strengthened its position as a provider of interoperable medical imaging infrastructure capable of improving healthcare coordination and enabling secure access to medical imaging across providers, patients, diagnostic centres and education institutions.

During the year, the Group focused on the following key activities:

- Successful deployment of 750 3DICOM™ MD® licences across Provider Network Solutions' (PNS) Primary Care Provider network, achieving contractual deployment milestones and receiving the contracted US$500,000 licence payment in April 2026.

- Progressed commercial expansion opportunities with significant U.S. healthcare organisations, including Triple-S health plan, strengthening the Group's healthcare payer pipeline.

- Successful deployment of 3DICOM™ Patient at Life Radiology in Florida, with more than 230 patients enrolled, further validating the Group's cloud-based patient imaging platform and the 3DICOM™ Gateway imaging sharing solution.

- Executed and commenced implementation of the Miami-Dade County Public Schools (M-DCPS) paid pilot, expanding the Group's presence within the U.S. healthcare education sector.

- Achieved FDA 510(k) clearance for the browser-based 3DICOM™ MD® Cloud platform, expanding diagnostic imaging support to include CT, MRI, PET, X-ray and ultrasound.

- Maintained compliance with ISO 27001, HIPAA and SOC 2 Type II, while progressing toward HITRUST certification to support large enterprise healthcare customers.

- Strengthened the Group's intellectual property portfolio following a favourable World Intellectual Property Organization (WIPO) patentability opinion for the Medical File Transfer Protocol (MFTP), with national phase filings progressing across multiple international jurisdictions.

Further details are provided below on key operational workstreams for the Company.

Commercial Activities

Continuous Collaboration with Provider Network Solutions (PNS)

The Group continued to strengthen its commercial relationship with Provider Network Solutions ("PNS"), one of the Group's key strategic healthcare partners in the United States.

During FY26 the Group completed deployment of an additional 500 3DICOM™ MD® licences, increasing the installed base to 750 Primary Care Provider licences across the PNS network.

The expanded deployment continues to generate valuable operational and clinical data supporting assessment of the platform's ability to reduce unnecessary duplicate imaging, improve interoperability between providers and deliver measurable healthcare cost savings. Preliminary deployment data and feedback provided by PNS indicated improvements in care coordination and reductions in unnecessary imaging utilisation. The Group continues to collect and assess operational and economic outcomes from the deployment.

During the year the Group received the contracted US$500,000 licence payment under the Binding Enterprise Agreement and commenced discussions regarding renewal of the current licensing arrangement together with opportunities to expand deployment across the broader PNS network.

At year end, discussions were continuing regarding renewal of the existing licensing arrangement, which was due to expire during Q3 CY2026, and the potential expansion of deployment across the broader PNS network.

Beyond the existing deployment, the Group and PNS continued pursuing opportunities across affiliated organisations, managed service organisations and healthcare payers throughout the United States.

Expansion into Healthcare Payers

Building on the commercial validation achieved through PNS, the Group continued expanding discussions with healthcare payers across the United States.

The Group progressed strategic discussions with Triple-S regarding deployment of an enterprise imaging platform incorporating 3DICOM™ Gateway, 3DICOM™ MD®, 3DICOM™ Patient, AI-in-the-Cloud and workflow solutions supporting Utilisation Management (UM) and Radiology Benefit Management (RBM).

Throughout the year, the executive team also continued engaging with additional healthcare organisations while further evaluating enterprise imaging infrastructure opportunities capable of reducing duplicate imaging, improving care coordination and strengthening utilisation management.

Collectively, these initiatives reinforce the Group's strategy of positioning 3DICOM™ as enterprise healthcare infrastructure supporting large health plans and managed service organisations in the effort of saving costs by reducing duplicate and unnecessary imaging.

Provider and Diagnostic Imaging

The Group continued expanding deployment of the 3DICOM™ platform across healthcare providers through the Life Radiology pilot in Miami, Florida.

The deployment combines 3DICOM™ Gateway and 3DICOM™ Patient to provide patients and referring clinicians with immediate secure access to medical imaging without reliance on CDs or physical media.

By 30 June 2026, more than 230 patients had enrolled in the deployment. The pilot provided an operating reference site for 3DICOM™ Gateway and 3DICOM™ Patient, with the Company continuing to monitor patient engagement, utilisation and workflow outcomes.

Education & Research

During FY26, the Group continued expanding the application of the 3DICOM™ platform within healthcare education.

Implementation activities progressed across the Miami-Dade County Public Schools (M-DCPS) deployment. During the June quarter, the Group completed multiple stakeholder workshops, provisioned administrative users and progressed implementation planning in preparation for student onboarding. The first student cohort was scheduled to commence activities in September 2026.

The deployment represents an important opportunity to validate the educational capabilities of 3DICOM™ EDU while supporting future expansion across secondary, tertiary and allied health education. The paid pilot was initially designed to provide access across five M-DCPS Technical Colleges for up to 150 students and instructors.

Government and Strategic Infrastructure Initiatives

During FY26, the Group continues its involvement in the Florida Statewide Imaging Repository initiative, which includes a requested project funding amount to the State of Florida which is anticipated to be substantive to the Group.

This project proposes the creation of a statewide imaging repository capable of receiving, storing and analysing medical imaging data and associated radiology reports generated by Medicaid-enrolled providers throughout Florida.

Management continues to view this initiative as a transformational opportunity capable of demonstrating the value of interoperable imaging infrastructure at statewide scale while generating meaningful commercial outcomes. The Group expects an outcome regarding the requested project funding in Q3 CY2026.

During FY26, the Group also entered into a Memorandum of Understanding with Florida International University to establish a framework for evaluating 3DICOM™ across medical education, clinical workflows and research environments. The proposed deployment encompasses 3DICOM™ EDU, 3DICOM™ MD®, 3DICOM™ Patient and repository capabilities.

Technical Development of 3DICOM™ Software

Development throughout FY26 remained closely aligned with active commercial opportunities and the Group's strategy of delivering an interoperable healthcare imaging ecosystem.

Key development initiatives included expanding healthcare workflow capabilities for Primary Care Providers, Utilisation Management teams and Radiology Benefit Managers, enabling structured imaging request, prior imaging searches, secure image sharing and imaging appropriateness assessments.

The Group also continued development of modular integrations supporting Radiology Information Systems (RIS), Laboratory Information Systems (LIS) and Electronic Health Record (EHR) platforms, further strengthening interoperability across enterprise healthcare environments.

Additional development activities included expansion of enterprise onboarding resources through a dedicated learning platform together with continued enhancement of 3DICOM™ EDU, including continued investigation and development of AI-enabled educational capabilities for interactive teaching and learning.

The Group also collaborated with Talk2View on an application under the Cooperative Research Centres Projects program. The proposed project seeks to integrate AI-assisted visual communication capabilities into the 3DICOM™ platform. No assurance can be given that the application will be successful.

Regulatory, Standards and Security

Maintaining strong governance, regulatory compliance and information security remained a strategic priority throughout FY26.

During the year the Group maintained compliance with ISO 27001, HIPAA and SOC 2 Type II while continuing implementation activities toward HITRUST certification. In parallel, an independent information security threat and risk assessment identified no evidence of active compromise and no critical or high-risk issues. It also provided recommendations for further strengthening testing, access controls and proactive monitoring as the Group scales.

These achievements reinforce the maturity of the Group's governance framework and strengthen its ability to support enterprise healthcare providers, health plans and government agencies.

Earlier in the financial year the Group also achieved FDA 510(k) clearance for the cloud-based version of 3DICOM™ MD®, significantly expanding the clinical applicability of the platform through browser-based deployment supporting CT, MRI, PET, X-ray and ultrasound imaging.

The Group also contributed to the US Office of the National Coordinator for Health Information Technology’s consultation on diagnostic imaging interoperability, providing policy and technical input informed by its deployment experience.

Intellectual Property

During FY26, The Group continued strengthening its global intellectual property portfolio.

Following the favourable International Preliminary Report on Patentability issued by the World Intellectual Property Organization (WIPO), national phase filings for the Group's Medical File Transfer Protocol (MFTP) progressed across Australia, the United States, Europe, Canada, Brazil, Mexico, Colombia, Indonesia and Vietnam.

The favourable opinion confirmed that all examined claims were both novel and inventive, substantially strengthening the Group's global intellectual property position and supporting future commercialisation opportunities.

Activities Subsequent to Period End

Subsequent to FY26, the Group executed a Memorandum of Understanding with Stellae Health, a member of the Provider Network Solutions (PNS) network, to undertake a pilot deployment of the 3DICOM™ platform across eight participating primary care practices. The pilot will evaluate the platform's ability to improve provider access to external medical imaging and radiology reports, streamline imaging workflows, enhance visibility of prior studies and support reductions in unnecessary repeat imaging. This agreement further extends the Company's presence within the growing PNS network and reinforces the increasing commercial traction of the 3DICOM™ platform across healthcare providers seeking interoperable imaging infrastructure solutions. Subject to successful pilot outcomes, the collaboration provides a pathway for broader deployment opportunities, including additional providers, imaging centres and integration initiatives.

Outlook

The Group enters FY27 with a significantly strengthened commercial pipeline across healthcare payers, providers, education and government.

The executive team remains focused on progressing healthcare payer opportunities toward commercial deployment, supporting expansion of the PNS relationship, advancing the Florida Statewide Imaging Repository, expanding provider deployments and continuing development of enterprise healthcare workflow capabilities.

The Board believes these initiatives position the Group to continue executing its strategy of becoming a leading provider of interoperable healthcare imaging infrastructure while creating long-term shareholder value.

6. Material business risks

6.1 Protection and ownership of intellectual property rights

The Group seeks to protect its intellectual property through patents, trademarks, trade secrets, copyright and know-how. Whilst the Group protects its intellectual property through these measures, there can be no guarantee that there will not be any unauthorised use or misuse of its intellectual property or reverse engineering of its software by competitors.

If the Group fails to protect its intellectual property, competitors may gain access to proprietary information which could harm the Group's business.

There is a risk that the Group will not be able to register or otherwise protect new intellectual property it develops in the future. Competitors may be able to work around any of the applications or other intellectual property rights used by the Group, or independently develop technologies or competing products that are not covered by the Group's intellectual property rights. This may materially adversely impact the Group's revenue, legal expenses and profitability.

If the Group believes its intellectual property rights have been infringed, it may initiate or otherwise be involved in litigation against third parties for infringement, or to establish the validity, of the Group's rights. Any litigation, whether or not successful, could result in significant expense to the Group and divert the efforts of its personnel. In addition, any infringement could result in revenue loss and may be detrimental to the Group’s reputation and brand value.

SThe Group’s commercial success is, to a large extent, reliant upon its intellectual property being suitably protected and providing the Group with enforceable rights (through the registration of patents and trademarks). The Group cannot give assurance that the patents, trademarks or other intellectual property in existence today or created in the future will be able to be adequately protected.

6.2 Reliance on senior personnel

The Group's operational success will depend substantially on the continuing efforts of its key management personnel and on its ability to attract and retain key quality staff and consultants.

The Group relies on experienced managerial and highly qualified technical staff to develop and operate its technology and to direct operational staff to manage the operational, sales, compliance and other functions of its business.

The loss of one or more of the Group's key management personnel could have an adverse impact on the Group's operations and financial performance. The Group's key personnel include its Managing Director, Chief Operating Officer, and Chief Commercial Officer. Although these individuals have entered into contracts with the Group, there is no assurance that such contracts will not be terminated. If such contracts are terminated or breached, or if these individuals no longer continue in their current roles, new personnel will need to be employed, which may adversely affect the business.

The Group is substantially dependent on the continued service of its existing development personnel due to the complexity of its products and technologies. There is no assurance that the Group will be able to retain the services of these people or that the Group will be able to recruit suitably qualified and talented staff in a time frame that meets the growth objectives of the Group.

6.3 Additional requirements for capital

As the Group's current business grows, and new lines of business are developed, the Group will require additional funding to support the ongoing development and commercialisation of its technology and to provide working capital. Although the Directors believe that the Group will have sufficient working capital and capacity to carry out its short-term business objectives, there can be no assurance that such objectives can be met without further financing or, if further financing is necessary, that financing can be obtained on favourable terms or at all. Further, if additional funds are raised by issuing shares, this may result in dilution for some or all of the shareholders. Any inability to obtain financing (if required) would have a material adverse effect on the group's business, financial condition and results of operations.

6.4 Certification of new applications / products and clinical trials

The Group has identified numerous certifications further to the FDA510(k) clearance issued in October 2022 that may allow for the use of 3DICOM™ in a diagnostic capacity including, TGA Class II, Health Canada clearance and CE Approval for the use of 3DICOM™ as a diagnostic SaMD.

The Group is also developing a number of new applications in the fields of anatomical education and artificial intelligence. These new products, as well as any future iterations of 3Dicom, may require continual clearances for new diagnostic and/or surgical planning tools and any new features may be required to undergo clinical studies and those studies may show that the new products or the new features (as the case may be) do not work in a safe and effective manner or that they do not meet the standards required for commercial release. If the new products or the new features do meet the required standards (and there is no guarantee that they will) then there is a risk that the Group will not be able to compete with other clinically approved technological developments in the market sectors in which it operates.

The Group may conduct clinical studies of new software it develops in the future, but there can be no guarantee that relevant regulatory agencies will allow the Group to undertake such trials and/or the development and approval process for any new products or applications of existing products may take longer, cost more than expected and may result in the new software not producing a viable device.

Depending upon the severity of any failure of the Group to comply with any applicable regulations, the Group could be subject to enforcement actions, including but not limited to warning letters, fines, injunctions, consent decrees, civil monetary penalties, recalls or seizures of its devices, manufacturing restrictions, closure of its manufacturing factories, modifications or revocations of any clearances and approvals that it already holds or will hold, and/or criminal prosecution. If any such sanctions are imposed against the Group, such sanctions could harm the Group's reputation and, depending upon the severity, could have significant adverse impact on the Group's ability to provide services and on its financial performance and condition.

6.5 Competition

The industry in which the Group is involved is subject to increasing global competition which is fast-paced and fast-changing. The Group will have no influence or control over the activities of its competitors, whose activities or actions may negatively affect the operating and financial performance of the Group's business. For instance, competing companies may develop technology that supersedes Singular Health's technology.

The size and financial strength of some of the Group's competitors may make it difficult for Singular Health to maintain a competitive position in the medical technology market. A number of third-party competitors are offering products and services similar to the Group's products. Existing competitors and new competitors entering into the industry may develop superior technology offerings or have enhanced scale benefits, which may have a material adverse effect on the Group's revenue and financial performance.

6.6 Medical or product liability risk

Generally, medical technology companies may be subject to claims alleging negligence, product liability or breach of warranty that may involve large claims and significant defence costs whether or not such liability is imposed. These claims may be brought by individuals seeking relief for themselves, or increasingly, by Companies seeking to represent a class. Claims could be made against the Group for liabilities resulting from adverse medical consequences to patients.

6.7 Privacy risks

The Group collects, stores and processes highly sensitive, highly regulated and confidential medical imaging data. There is a risk that the measures the Group takes may not be sufficient to detect or prevent unauthorised access to, or disclosure of, information collected in relation to the Group's customers, end-user patients, employees and other sources of personal information. This may expose the Group to reputational damage, legal claims, termination of the Group's contracts, and regulatory scrutiny and fines, any of which could materially adversely impact the financial performance and prospects of the Group.

The Group's security measures are subject to various risks including failure of end-users to comply with instructions for use, computer viruses, physical theft, physical damage resulting in a loss or corruption of data, operating system failures or similar disruptions. There is a risk that failure to adequately safeguard against any and all of these risks may result in a data breach, or a third party may gain access to confidential information of Singular Health's customers, end-user patients or employees.

In addition, any security or data issues experienced by other software companies globally could adversely impact client's trust in providing access to personal data generally, which could adversely affect the Group's ability to provide its service generally.

6.8 Technology changes

The Group participates in a competitive environment. Information technology systems are continuing to develop and are subject to rapid change, while business practices continue to evolve. The Group's success will in part depend on its ability to offer services and systems that remain current with the continuing changes in technology, evolving industry standards and changing consumer preferences. There is a risk that the Group will not be successful in addressing these developments in a timely manner, or that expenses will be greater than expected. In addition, there is a risk that new products or technologies (or alternative systems) developed by third parties will supersede the Group's technology. This may materially and adversely impact the Group's income and profitability.

6.9 Regulatory risks

The Group's operations may become subject to regulatory requirements, such as licensing and reporting obligations, which would increase the costs and resources associated with regulatory compliance. Any such increase in the costs and resources associated with regulatory compliance could impact upon the Group's income. In addition, if regulators took the view that the Group had failed to comply with regulatory requirements, this could lead to enforcement action resulting in public warnings, infringement notices or the imposition of a pecuniary penalty. This could lead to significant damage to the Group's reputation and consequently impact on its income.

The Group may offer its products, and any future developed products, throughout the world. Regulatory changes could see the Group being required to hold a license in some of these jurisdictions or otherwise comply with local regulations. This could preclude the Group from offering certain services in these jurisdictions until such a license has been obtained or may require the Group to comply with a range of regulatory requirements. Any such increase in the costs and resources associated with the regulatory compliance in these jurisdictions could impact upon the Group's income.

7. Dividends
There were no dividends paid, recommended or declared during the current or previous financial year.

8. Likely developments and expected results of operations
Information on likely developments in the operations of the Group and the expected results of operations have not been included in this report because the Directors believe it would be likely to result in unreasonable prejudice to the Group.

9. Significant changes in the state of affairs
There were no significant changes in the state of affairs of the Group during the financial year.

10. Matters subsequent to the end of the financial year

Date	Details
30 July 2026	The Group's subsidiary Singular 3Dicom Solutions USA Pty Ltd (ACN 686 594 249) entered into and gave effect to a Stock Purchase Agreement to acquire 4,166,667 shares of common stock in Singular Imaging Solutions-US, Inc. ("SIS-US"), a Delaware corporation, from Marin & Sons Strategies, LLC for cash consideration of USD 175,000. Prior to the transaction, the Group held 4,285,710 shares, being 30% of SIS-US. Following the transaction the Group holds 8,452,377 shares, being approximately 60% of the issued and outstanding common stock, and has obtained control of SIS-US. The remaining 40% is held by PNS Singular, LLC (30%) and PNS PR MSO Holding, LLC (10%), both of which approved the transaction by written consent on 27 July 2026. From 30 July 2026 SIS-US will be consolidated as a controlled entity and a non-controlling interest will be recognised. The acquisition will be accounted for as a business combination achieved in stages, which requires the Group's previously held 30% interest to be remeasured to fair value at the acquisition date, with any resulting gain or loss recognised in profit or loss. At the date of this report the initial accounting for the acquisition is incomplete and the fair values of the identifiable assets acquired and liabilities assumed have not been finalised. Accordingly, the financial effect of the acquisition cannot yet be reliably estimated and will be disclosed in the Group's financial statements for the year ending 30 June 2027.

No other matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

11. Environmental regulation
The Group is not subject to any significant environmental regulation under Australian Commonwealth or State law.

12. Shares options
a. Unissued shares under options
Unissued ordinary shares of Singular Health Group Limited under option at the date of this report are as follows:

Issue Date	Expiry date	Exercise price	Number under option
09-Feb-24	9-Feb-27	$0.100	7,727,272
10-Nov-24	8-Dec-27	$0.080	15,500,000
27-Jun-24	8-Dec-27	$0.080	2,062,500
25-Jul-24	25-Jul-27	$0.150	3,138,000
28-Nov-24	28-Nov-27	$0.150	9,000,000
19-Feb-25	19-Feb-28	$0.150	6,325,000
15-Apr-25	15-Apr-28	$0.250	2,000,000
15-Apr-25	15-Oct-28	$0.250	5,000,000
15-Apr-25	15-Apr-29	$0.250	10,000,000
26-Jun-25	26-Jun-28	$0.550	10,000,000
18-Dec-25	30-Nov-29	$0.550	6,000,000
			76,752,772

No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the Company or of any other body corporate.

b. Shares issued on the exercise of options

The following ordinary shares of Singular Health Group Limited were issued during the year ended 30 June 2026 and up to the date of this report on the exercise of options granted as follows (there are no amounts unpaid on the shares issued):

Date options exercised	Exercise price	Number of shares issued
8-Aug-25	$0.100	1,818,181
10-Sep-25	$0.100	381,818
20-Nov-25	$0.100	509,091
9-Dec-25	$0.150	900,000
19-Jan-26	$0.200	1,720,000
9-Apr-26	$0.100	272,728
1-May-26	$0.100	363,636
4-May-26	$0.100	420,000
26-Jun-26	$0.100	2,571,222
		8,956,676

13. Shares under performance rights

a. Unissued shares under performance rights

Unissued ordinary shares of Singular Health Group Limited under performance rights at the date of this report are as follows:

Grant date	Expiry date	Exercise price	Number under rights
25-Jul-24	30-Jun-28	$0.000	10,000,000

No person entitled to exercise the performance rights had or has any right by virtue of the performance right to participate in any share issue of the Company or of any other body corporate.

b. Shares issued on the exercise of performance rights

The following ordinary shares of Singular Health Group Limited were issued during the year ended 30 June 2026 and up to the date of this report on the exercise of performance rights granted:

Date performance rights exercised	Exercise price	Number of shares issued
08-Aug-25	$0.000	950,000
10-Sep-25	$0.000	4,500,000
		5,450,000

14. Indemnity and insurance of officers and auditors

The Group has indemnified the Directors and executives of the Group for costs incurred, in their capacity as a Director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Group paid a premium in respect of a contract to insure the Directors and executives of the Group against a liability to the extent permitted by the *Corporations Act 2001*. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

The Group has not otherwise, during or since the end of the financial year, except to the extent permitted by law, indemnified or agreed to indemnify an officer or auditor of the Group or of any related body corporate against a liability incurred as an officer or auditor.

15. Non-audit services

Details of the amounts paid or payable to the auditor for non-audit services provided during the financial year by the auditor are outlined in **note 24** to the financial statements.

The Directors are satisfied that the provision of non-audit services during the financial year, by the auditor (or by another person or firm on the auditor's behalf), is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001*.

The Directors are of the opinion that the services as disclosed in **note 24** to the financial statements do not compromise the external auditor's independence requirements of the *Corporations Act 2001* for the following reasons:

- all non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor; and
- none of the services undermine the general principles relating to auditor independence as set out in APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)*, including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the Group, acting as advocate for the Group or jointly sharing economic risks and rewards.

16. Proceedings on behalf of the Company

No person has applied to the Court under section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

17. Rounding off

The Group is of a kind referred to in *ASIC Corporations* (Rounding in Financial/Directors' Reports) *Instrument 2026/183* and in accordance with that Instrument, amounts in the consolidated financial statements and directors' report have been rounded off to the dollars, unless otherwise stated.

18. Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out immediately after this Directors' report.

19. Remuneration report (audited)

The remuneration report details the key management personnel remuneration arrangements for the Group, in accordance with the requirements of the *Corporations Act 2001* and its Regulations.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Group, directly or indirectly, including all Directors.

The remuneration report is set out under the following main headings:
- 19.1 Principles used to determine the nature and amount of remuneration
- 19.2 Details of remuneration
- 19.3 Service agreements
- 19.4 Share-based compensation
- 19.5 Additional information
- 19.6 Additional disclosures relating to key management personnel

19.1 Principles used to determine the nature and amount of remuneration

(a) Introduction

Key Management Personnel (KMP) have authority and responsibility for planning, directing and controlling the major activities of the Group. KMP comprise the directors of the Company and identified Key Management Personnel.

(b) Remuneration Governance

The objective of the Group's executive reward framework is to ensure reward for performance is competitive and appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic objectives and the creation of value for shareholders, and it is considered to conform to the market best practice for the delivery of reward. The Board of Directors ('the Board') ensures that executive reward satisfies the following key criteria for good reward governance practices:
- Competitiveness and reasonableness,
- Acceptability to shareholders,
- Performance linkage / alignment of executive compensation, and
- Transparency.

The reward framework is designed to align executive reward to shareholders' interests. The Board have considered that it should seek to enhance shareholders' interests by:
- having economic profit as a core component of plan design,
- focusing on sustained growth in shareholder wealth, consisting of dividends and growth in share price, and delivering constant or increasing return on assets as well as focusing the executive on key non-financial drivers of value, and
- attracting and retaining high calibre executives.

Additionally, the reward framework should seek to enhance executives' interests by:
- rewarding capability and experience,
- reflecting competitive reward for contribution to growth in shareholder wealth, and
- providing a clear structure for earning rewards.

In accordance with best practice corporate governance, the structure of non-executive Director and executive Director remuneration is separate.

(c) Non-executive Directors remuneration

The Constitution and ASX listing rules require the aggregate non-executive Directors' remuneration be determined periodically by a general meeting. The most recent determination was at the Annual General Meeting held on 28 November 2022, where the shareholders approved a maximum annual aggregate remuneration of $500,000.

(d) Executive remuneration

The Group aims to reward executives based on their position and responsibility, with a level and mix of remuneration which has both fixed and variable components.

The executive remuneration and reward framework has four components:
- base pay and non-monetary benefits
- short-term performance incentives
- share-based payments
- other remuneration such as superannuation and long service leave

The combination of these comprises the executive's total remuneration.

Directors' fees
The amount of remuneration of the non-executive directors receive must not exceed the fixed sum of $500,000 per annum as approved at the General Meeting on 28 November 2022.

Remuneration of executives consists of an un-risked element (base pay) and performance-based bonuses based on performance in relation to key strategic, non-financial measures linked to drivers of performance in future reporting periods. A performance-based bonus was accrued for Denning Chong for the financial year ended 30 June 2025 and paid subsequent to 30 June 2025.

Additional fees
A Director may also be paid fees or other amounts as the Directors determine if a Director performs special duties or otherwise performs services outside the scope of the ordinary duties of a Director.

A Director may also be reimbursed for out-of-pocket expenses incurred as a result of their directorship or any special duties.

Retirement allowances for directors
Superannuation contributions required under Australian superannuation guarantee legislation continue to be made and are deducted from the directors' overall fee entitlements where applicable.

Executive pay
In determining executive remuneration, the Board aims to ensure that remuneration practices are:

- competitive and reasonable, enabling the company to attract and retain key talent;
- aligned to the company's strategic and business objectives and the creation of shareholder value;
- transparent; and
- acceptable to shareholders.

The executive remuneration framework has four components:

- base pay and non-monetary benefits;
- short-term performance incentives;
- other remuneration such as superannuation and long-service leave; and
- long-term incentives through participation in the Singular Employee Share Option Plan.

Base pay
Executives receive their base pay and benefits structured as a total employment cost (TEC) package which may be delivered as a combination of cash and prescribed non-financial benefits at the executives' discretion.

Executives are offered a competitive base pay that comprises the fixed component of pay and rewards. Independent remuneration consultants provide analysis and advice to ensure base pay is set to reflect the market for a comparable role.

Base pay for executives is reviewed annually to ensure the executive's pay is competitive with the market. An executive's pay is also reviewed on promotion.

There is no guaranteed base pay increases included in any executives' contracts.

Benefits
No benefits other than noted above are paid to Directors or Management except as incurred in normal operations of the business.

Short term incentives
No benefits other than remuneration disclosed in the remuneration report are paid to Directors or Management except as incurred in normal operations of the business.

Managing Director Denning Chong received a short term incentive based on achieving a number of key performance indicators that were chosen to align his performance with milestones that would be indicators of positive growth for the company and reflective of increasing shareholder value during the financial year (FY26).

These key performance indicators considered included a successful pilot with PNS, a contract with a second MSO and or Health payer outside of Triple S, recruitment of a CCO based in the USA, a Material Contract with an education institution or any other end user with value exceeding USD$300,000 Annual Recurring Revenue, the further purchase of licenses by PNS of minimum 250 MD licenses, a contract with another Health payer and or MSO within the PNS partner network, and 10% Percentage of sales for year 1 July 2025 to 30 June 2026 or percentage as board determines, or period to which Board determines (but no earlier than 30 June 2026).

Long term incentives
During the year, the Company issued unlisted options and performance rights to the Directors and KMP. The details of the options issued are disclosed in ***19.4 Share-based compensation*** of the remuneration report.

Remuneration consultants
The Company engaged Reward Partners remuneration consultants during the year to provide input on the salary and remuneration of the Group's CEO, including short term and long-term incentive structures.

The Group will continue to engage independent remuneration consultants should it look to make any changes to director fee levels to ensure they are in line with market conditions and any decisions are made free from undue influence from members of the Group's KMP's. During the year, no consultant fees were paid.

Group performance and link to remuneration
Remuneration for certain individuals is directly linked to the performance of the Group. The relative proportions of remuneration that are linked to performance and those that are fixed are disclosed ***19.2 Details of Remuneration*** of the remuneration report. The proportion of remuneration that is linked to performance relates to the vesting of performance rights issued to key management personnel, the terms of which are disclosed in ***19.4 Share-based compensation*** of this report. The Directors assess performance of the Group with regard to the achievement of both operational and financial targets with a focus on sales revenues and share price. Directors and employees are issued performance rights to encourage the alignment of personal and shareholder interests.

Voting and comments made at the Company's 19 November 2025 Annual General Meeting ('AGM')
At the 19 November 2025 AGM, 93.04% of the votes received supported the adoption of the remuneration report for the year ended 30 June 2025. The Company did not receive any specific feedback at the AGM regarding its remuneration practices.

19.2 Details of remuneration
Amounts of remuneration
Details of the nature and amount of each major element of remuneration of each Director of the Company, and other key management personnel of the Group are set out in the following tables.

- Howard Digby (Non-Executive Chairman)
- Denning Chong (Managing Director and Chief Executive Officer)
- Andrew Just (Non-Executive Director)
- Martina Mariano (Chief Operating officer)
- Paige Taylor (Chief Commercial Officer) appointed 15 September 2025

30 June 2026	Short-term benefits			Post-employment benefits		
	Cash salary and fees $	Cash bonus $	Annual leave $	Super-annuation $	Share-based payments $	Total $
Non-Executive Directors:						
Howard Digby	72,500	-	-	8,700	60,089	141,289
Andrew Just	62,500	-	-	7,500	60,089	130,089
Executive Directors:						
Denning Chong[1]	250,000	135,000	30,592	30,000	1,051,965	1,497,557
Other Key Management Personnel:						
Martina Mariano	220,000	-	24,373	26,400	-	270,773
Paige Taylor[2]	293,067	-	-	-	-	293,067
James Hill[3]	14,526	-	-	3,974	-	18,500
	912,593	135,000	54,965	76,574	1,172,143	2,351,275

[1] A cash bonus relating to Mr Denning's performance during the financial year ended 30 June 2026 was accrued at year end and subsequently paid in July 2026. Refer **Section 19.1 *Short term incentives*** for details.

[2] Remuneration from commencement of employment 15 September 2025.

[3] resignation on 27 June 2025. This was paid out of his annual leaves for services rendered during financial period 30 June 2025.

30 June 2025	Short-term benefits			Post-employment benefits		
	Cash salary and fees $	Cash bonus $	Annual leave $	Super-annuation $	Share-based payments $	Total $
Non-Executive Directors:						
Howard Digby	50,000	-	-	5,750	70,227	125,977
Andrew Just	40,000	-	-	4,600	70,227	114,827
Executive Directors:						
Denning Chong[5]	250,000	135,000	38,777	28,750	2,072,340	2,524,867
Other Key Management Personnel:						
James Hill[6]	161,593	-	6,978	17,876	141,831	328,278
Martina Mariano	149,429	-	33,732	17,184	54,293	254,638
	651,022	135,000	79,487	74,160	2,408,918	3,348,587

[5] Bonus was paid subsequent to 30 June 2025 in accordance with the Executive Service Agreement dated 11 October 2023 effective since 1 July 2024, a $135,000 Short-Term Incentive (STI) achieved based on the milestones and it was approved by the Board. The criteria were disclosed in **19.3 Service Agreement**.

[6] Remuneration up to date of resignation 27 June 2025.

The proportion of remuneration linked to performance and the fixed proportion are as follows:

Name	Fixed remuneration 30 June 2026	Fixed remuneration 30 June 2025	At risk - STI 30 June 2026	At risk - STI 30 June 2025	At risk - LTI 30 June 2026	At risk - LTI 30 June 2025
Non-Executive Directors:						
Andrew Just	54%	39%	-	-	46%	61%
Howard Digby	57%	44%	-	-	43%	56%
Executive Directors:						
Denning Chong	15%	13%	7%	6%	78%	81%
Other Key Management Personnel:						
Martina Mariano	100%	79%	-	-	-	21%
James Hill	-	57%	-	-	-	43%

The proportion of the cash bonus paid/payable or forfeited is as follows:

Name	Cash bonus paid/payable 30 June 2026	Cash bonus paid/payable 30 June 2025	Cash bonus forfeited 30 June 2026	Cash bonus forfeited 30 June 2025
Executive Directors:				
Denning Chong	100%	100%	-	-

Mr Chong was awarded a cash bonus in recognition of his performance and contribution during the year ended 30 June 2026. The bonus formed part of Mr Denning's short-term incentive remuneration and was accrued as at 30 June 2026. Payment of the bonus was made in July 2026. Refer **Section 19.1** ***Short term incentives*** for details.

19.3 Service agreements

Executive Service Agreements

Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Name:	**Denning Chong**
Title:	Managing Director and Chief Executive Officer
Agreement commenced:	15 April 2023
Term of agreement:	Termination by either party on notice of 4 months.
Details:	Base salary including director fees for the year ending 30 June 2026 of $250,000 per annum plus superannuation.

Name:	**Martina Mariano**
Title:	Chief Operating officer
Agreement commenced:	9 February 2024 with subsequent variations.
Term of agreement:	Termination by either party on notice of 4 weeks.
Details:	Base salary for the year ending 30 June 2026 of $230,000 per annum plus superannuation.

Name:	**Paige Taylor**
Title:	Chief Commercial Officer (appointed 15 September 2025)
Agreement commenced:	15 September 2025
Term of agreement:	Termination by either party on notice of 120 days.
Details:	Base salary for the year ending 30 June 2026 of USD$250,000 per annum (equivalent to AUD 293,067). Annual bonus - For CY 2026, the Executive's annual target bonus opportunity shall be equal to 100% of base salary (the "Target Bonus"), based on the achievement of Company and Executive performance goals established by the Board, provided that, depending on results, the Executive's actual bonus may be higher or lower than the target bonus, as determined by the Board. This is not due until September 2026. Equity Awards - On the date of 6 months following 15 September 2025, the Company will grant the Executive 3 million Equity Incentive Plan Option, subject to Board approval. The options grant date is out-of-the money and represent approximately 0.7% of SHG's outstanding equity, at a strike price to be mutually agreed, but no less than AUD 55 cents. Such options shall vest in four equal annual installments, which first installment vesting on the first anniversary of the effective date and remaining installments vesting on each of the next three anniversaries thereafter. This was yet to be earned as at 30 June 2026 as such deferred to next financial period.

Non-executive directors

On appointment to the Board, all non-executive directors enter into a service agreement with the Group in the form of a letter of appointment. The letter summarises the Board’s policies and terms, including compensation, relevant to the director, and among other things:

- the terms of the Directors' appointment, including governance, compliance with the Company’s Constitution, committee appointments, and re-election.
- the Directors' duties, including disclosure obligations, exercising powers, use of office, attendance at meetings and commitment levels.
- the fees payable, in line with shareholder approval, any other terms, timing of payments and entitlements to reimbursements.
- insurance and indemnity.
- disclosure obligations; and
- confidentiality.

The following fees (exclusive of superannuation) were applicable during the financial year. These became effective from 1 October 2025.

Name	Base fee p.a (previous)	Base fee p.a (current)
Mr. Howard Digby	$50,000	$80,000
Mr. Andrew Just	$40,000	$70,000

19.4 Share-based compensation

Unlisted options

The terms and conditions of each grant of options over ordinary shares affecting remuneration of Directors and other Key Management Personnel in this financial year is as follows:

Name	Number of options granted	Grant date	Vesting date and exercisable date	Expiry date	Exercise price	Fair value per option at grant date
Denning Chong	3,000,000	19-Nov-25	30-Jun-26	30-Nov-29	$0.550	$0.1662
Denning Chong	3,000,000	19-Nov-25	30-Jun-27	30-Nov-29	$0.550	$0.1655

Options granted carry no dividend or voting rights.

All options were granted over unissued fully paid ordinary shares in the company. The number of options granted was determined having regard to the satisfaction of performance measures and weightings as described above in the section '**Group performance and link to remuneration**'. Options vest based on the provision of service over the vesting period whereby the executive becomes beneficially entitled to the option upon achieving share price vesting hurdle by the vesting date. Options are exercisable by the holder as from the vesting date. There has not been any alteration to the terms or conditions of the grant since the grant date. There are no amounts paid or payable by the recipient in relation to the granting of such options other than on their potential exercise.

Values of options over ordinary shares granted, exercised and lapsed for Directors and other key management personnel as part of compensation during the year ended 30 June 2026 are set out below:

Name	Value of options vested during the year $	Value of options exercised during the year $	Value of options lapsed during the year $	Remuneration consisting of options for the year %
Denning Chong	991,155	-	-	48%
Howard Digby	60,089	-	-	43%
Andrew Just	60,089	-	-	43%

Details of options over ordinary shares granted, vested and lapsed for Directors and other Key Management Personnel as part of compensation during the year ended 30 June 2026 are set out below:

Name	Grant date	Financial years in which grant vest	Number of options granted	Number of options vested	Number of options lapsed
Denning Chong	19-Nov-25	30-Jun-26	3,000,000	3,000,000	-
Denning Chong	19-Nov-25	30-Jun-27	3,000,000	-	-
Howard Digby	19-Mar-25	30-Jun-26	1,000,000	666,666	-
Andrew Just	19-Mar-25	30-Jun-26	1,000,000	666,666	-

Performance rights

The terms and conditions of each grant of performance rights over ordinary shares affecting remuneration of Directors and other key management personnel in this financial year are as follows:

Name	Number of rights granted	Grant date	Vesting date and exercisable date*	Expiry date	Share price hurdle for vesting	Fair value per right at grant date
Denning Chong	2,500,000	27-Jun-24	30-Jun-25	30-Jun-28	$0.200	$0.0694
Denning Chong	2,500,000	27-Jun-24	30-Jun-25	30-Jun-28	$0.250	$0.0650
Denning Chong	2,500,000	27-Jun-24	30-Jun-25	30-Jun-28	$0.300	$0.0612
Denning Chong	2,500,000	27-Jun-24	30-June-26	30-Jun-28	$0.350	$0.0486

* The performance rights subject to continuous employment and achievement of share price hurdle.

Performance rights granted carry no dividend or voting rights.

All performance rights were granted over unissued fully paid ordinary shares in the company. The number of performance rights granted was determined having regard to the satisfaction of performance measures and weightings as described above in the section '**Group performance and link to remuneration**'. Performance vest based on the provision of service over the vesting period whereby the executive becomes beneficially entitled to the rights upon achieving share price vesting hurdle by vesting date. There has not been any alteration to the terms or conditions of the grant since the grant date. There are no amounts paid or payable by the recipient in relation to the granting of such performance rights other than on their potential exercise.

There were no performance rights over ordinary shares granted to Directors and other key management personnel as part of compensation during the year ended 30 June 2026.

Values of performance rights over ordinary shares granted, vested and lapsed for Directors and other key management personnel as part of compensation during the year ended 30 June 2026 are set out below:

Name	Value of rights granted during the year $	Value of rights vested during the year $	Value of rights lapsed during the year $	Remuneration consisting of rights for the year %
Denning Chong	-	610,466	-	30%

Details of performance rights over ordinary shares granted, vested and lapsed for Directors and other key management personnel as part of compensation during the year ended 30 June 2026 are set out below:

Name	Grant date	Financial years in which grant vest	Number of rights granted	Number of rights vested	Number of rights lapsed
Denning Chong	27-Jun-24	30-Jun-26	2,500,000	2,500,000	-
	27-Jun-24	30-Jun-25	7,500,000	7,500,000	-

19.5 Additional information

The earnings of the Group for the five years to 30 June 2026 are summarised below:

	30 June 2026 $	30 June 2025 $	30 June 2024 $	30 June 2023 $	30 June 2022 $
Revenue and other income from continuing operations	2,343,870	702,021	1,249,022	1,033,769	54,034
Loss before income tax	(6,340,453)	(6,376,210)	(2,878,446)	(5,390,318)	(5,986,020)
Loss after income tax	(6,340,453)	(6,376,210)	(2,878,446)	(5,390,318)	(5,986,020)

The table below set out summary information about the Group's movement in shareholder wealth for the five years to 30 June 2026.

The factors that are considered to affect total shareholders return ('TSR') are summarised below:

	30 June 2026	30 June 2025	30 June 2024	30 June 2023	30 June 2022
Share price at financial year end ($)	0.21	0.38	0.10	0.03	0.09
Basic earnings per share (cents per share)	(2.03)	(2.69)	(3.08)	(4.90)	(5.83)
Diluted earnings per share (cents per share)	(2.03)	(2.69)	(3.08)	(4.90)	(5.83)

No dividends have been declared and paid for the year 30 June 2026 and 30 June 2025.

19.6 Additional disclosures relating to key management personnel

Shareholding

The number of shares in the Company held during the financial year by each Director and other members of Key Management Personnel of the Group, including their personally related parties, is set out below:

Ordinary shares	Balance at the start of year or at date of become as KMP	Received as part of remuneration	On exercise of options/rights	Disposals/ other	Balance at the end of year
Directors					
Denning Chong[1]	15,308,575	-	1,818,182	302,962	17,429,719
Andrew Just	336,364	-	-	-	336,364
Howard Digby[2]	680,609	-	-	41,666	722,275
Key Management Personnel					
Martina Mariano[3]	1,502,505	-	500,000	(400,000)	1,602,505
Paige Taylor	-	-	-	-	-
	17,828,053	-	2,318,182	(55,372)	20,090,863

(1) On 22 December 2025, 1,818,182 unlisted options were exercised at $0.10 per option and converted into ordinary shares for a total consideration of $181,818.

On 25 July 2025, Mr Denning Chong, Managing Director, acquired 302,962 ordinary shares on-market for a total consideration of $100,000.

(2) On 18 March 2026, Mr Howard Digby, Non-Executive Chairman, acquired 41,666 ordinary shares on-market for a total consideration of $10,000.

(3) On 8 August 2025, Ms Martina Mariano, Chief Operating Officer, exercised 500,000 performance rights into ordinary shares. These rights were subject to vesting conditions based on share price performance and continuous employment.

Option holding

The number of options over ordinary shares in the Company held during the financial year by each Director and other members of key management personnel of the Group, including their personally related parties, is set out below:

Options over ordinary shares	Balance at the start of year or at date of become as KMP	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of year
Directors					
Denning Chong	23,068,182	6,000,000	(1,818,182)	-	27,250,000
Andrew Just	2,000,000	-	-	-	2,000,000
Howard Digby	2,250,000	-	-	-	2,250,000
Key Management Personnel					
Martina Mariano	2,100,000	-	-	(100,000)	2,000,000
Paige Taylor	-	-	-	-	-
	29,418,182	6,000,000	(1,818,182)	(100,000)	33,500,000

Performance rights holding
The number of performance rights over ordinary shares in the Company held during the financial year by each Director and other members of key management personnel of the Group, including their personally related parties, is set out below:

Performance rights over ordinary shares	Balance at the start of year or at date of become as KMP	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of year
Directors					
Denning Chong	10,000,000	-	-	-	10,000,000
Andrew Just	-	-	-	-	-
Howard Digby	-	-	-	-	-
Key Management Personnel					
Martina Mariano[1]	500,000	-	(500,000)	-	-
Paige Taylor	-	-	-	-	-
	10,500,000	-	(500,000)	-	10,000,000

(1) On 8 August 2025, Ms Martina Mariano, Chief Operating Officer, exercised 500,000 performance rights into ordinary shares. These rights were subject to vesting conditions based on share price performance and continuous employment.

Loans to key management personnel and their related parties
No loans were provided to, made, guaranteed or secured directly or indirectly to any KMP or their related entities during the financial year.

Other transactions with key management personnel and their related parties
James Chong and Co Pty Ltd associated with Denning Chong, received $5,309 excluding GST (30 June 2025: $9,042) during the year for corporate legal advice and services. These services are provided on normal commercial terms and at arm's length, with nil balance payable as at 30 June 2026.

This concludes the remuneration report, which has been audited.

This report is made in accordance with a resolution of Directors, pursuant to section 298(2)(a) of the *Corporations Act 2001*.

On behalf of the Directors



____
Denning Chong
Managing Director

28 August 2026

AUDITOR'S INDEPENDENCE DECLARATION TO THE DIRECTORS OF SINGULAR HEALTH GROUP LIMITED AND ITS CONTROLLED ENTITIES

In accordance with section 307C of the *Corporations Act 2001*, I declare to the best of my knowledge and belief in relation to the audit of the financial report of Singular Health Group Limited and its controlled entities for the year ended 30 June 2026, there have been:

- no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- no contraventions of the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* in relation to the audit.

Pitcher Partners BA&A PTY LTD

PITCHER PARTNERS BA&A PTY LTD

PAUL MULLIGAN
Executive Director
Perth, 28 August 2026

Singular Health Group Limited
Consolidated statement of profit or loss and other comprehensive income
For the year ended 30 June 2026

	Note	30 June 2026 $	30 June 2025 $
Revenue			
Revenue from contracts with customer	5	1,428,231	203,069
Research and development grant income		471,540	354,539
Interest revenue calculated using the effective interest method		444,099	144,413
Expenses			
Selling and marketing expenses		(782,095)	(282,212)
Patent, research and development expenses		(1,187,294)	(643,826)
Corporate, legal and compliance expenses		(935,806)	(541,249)
Employee benefits expense		(3,240,057)	(1,699,775)
Depreciation and amortisation expense		(80,937)	(129,657)
Share-based payments	9	(2,089,670)	(3,265,133)
Administrative expenses		(320,661)	(323,837)
Other expenses		(37,904)	(67,970)
Finance costs		(9,899)	(10,423)
Loss before income tax expense from continuing operations		**(6,340,453)**	**(6,262,061)**
Income tax expense	10	-	-
Loss after income tax expense from continuing operations		(6,340,453)	(6,262,061)
Loss after income tax expense from discontinued operations	6	-	(114,149)
Loss after income tax expense for the year attributable to the owners of Singular Health Group Limited		**(6,340,453)**	**(6,376,210)**
Other comprehensive loss			
Items that may be reclassified subsequently to profit or loss			
Foreign currency translation		7,682	(4,558)
Other comprehensive loss for the year, net of tax		7,682	(4,558)
Total comprehensive loss for the year attributable to the owners of Singular Health Group Limited		**(6,332,771)**	**(6,380,768)**
		Cents	**Cents**
Loss per share for loss from continuing operations attributable to the owners of Singular Health Group Limited			
Basic loss per share	8	(2.03)	(2.64)
Diluted loss per share	8	(2.03)	(2.64)
Loss per share for loss attributable to the owners of Singular Health Group Limited			
Basic loss per share	8	(2.03)	(2.69)
Diluted loss per share	8	(2.03)	(2.69)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Singular Health Group Limited
Consolidated statement of financial position
As at 30 June 2026

	Note	30 June 2026 $	30 June 2025 $
Assets			
Current assets			
Cash and cash equivalents	**11**	2,362,017	628,648
Trade and other receivables	**13**	859,360	252,876
Financial assets	**14**	7,700,000	13,050,000
Other assets		91,086	133,213
Total current assets		11,012,463	14,064,737
Non-current assets			
Trade and other receivables	**13**	-	91,854
Property, plant and equipment		128,443	50,943
Right-of-use assets	**15**	89,979	-
Other assets		5,007	-
Total non-current assets		223,429	142,797
Total assets		**11,235,892**	**14,207,534**
Liabilities			
Current liabilities			
Trade and other payables		416,840	553,561
Contract liabilities	**16**	-	464,721
Lease liabilities	**17**	16,097	-
Provisions		172,395	92,699
Total current liabilities		605,332	1,110,981
Non-current liabilities			
Lease liabilities	**17**	93,866	-
Total non-current liabilities		93,866	-
Total liabilities		**699,198**	**1,110,981**
Net assets		**10,536,694**	**13,096,553**
Equity			
Issued capital	**18**	32,656,206	29,919,436
Reserves	**19**	8,098,867	7,055,047
Accumulated losses		(30,218,379)	(23,877,930)
Total equity		**10,536,694**	**13,096,553**

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

Singular Health Group Limited
Consolidated statement of changes in equity
For the year ended 30 June 2026

	Issued capital $	Share-based payment reserve $	Accumulated losses $	Foreign currency translation reserve $	Total equity $
Balance at 1 July 2024	16,430,777	5,911,597	(20,903,557)	2,391	1,441,208
Loss after income tax expense for the year	-	-	(6,376,210)	-	(6,376,210)
Other comprehensive loss for the year, net of tax	-	-	-	(4,558)	(4,558)
Total comprehensive loss for the year	**-**	**-**	**(6,376,210)**	**(4,558)**	**(6,380,768)**
Transactions with owners in their capacity as owners:					
Issue of ordinary shares **(note 18)**	13,323,000	(99,000)	-	-	13,224,000
Equity-settled share-based payments	80,000	3,185,134	-	-	3,265,134
Share options exercised	1,509,299	-	-	-	1,509,299
Performance rights exercised	1,003,324	(1,003,329)	-	-	(5)
Share options lapsed	-	(2,401,841)	2,401,841	-	-
Capital raising cost	(2,621,567)	2,454,648	-	-	(166,919)
Performance rights lapsed	-	(1,000,000)	1,000,000	-	-
Issue of options	-	10,000	-	-	10,000
Equity-settled director fees in lieu **(note 9)**	78,604	-	-	-	78,604
Equity-settled to ex directors - discontinued **(note 9)**	116,000	-	-	-	116,000
Balance at 30 June 2025	**29,919,437**	**7,057,209**	**(23,877,926)**	**(2,167)**	**13,096,553**

	Issued capital $	Share-based payment reserve $	Accumulated losses $	Foreign currency translation reserve $	Total equity $
Balance at 1 July 2025	29,919,437	7,057,209	(23,877,926)	(2,167)	13,096,553
Loss after income tax expense for the year	-	-	(6,340,453)	-	(6,340,453)
Other comprehensive income for the year, net of tax	-	-	-	7,682	7,682
Total comprehensive loss for the year	**-**	**-**	**(6,340,453)**	**7,682**	**(6,332,771)**
Transactions with owners in their capacity as owners:					
Issue of ordinary shares **(note 18)**	150,000	-	-	-	150,000
Equity-settled share-based payments **(note 9)**	849,552	1,339,120	-	-	2,188,672
Share options exercised	1,544,943	-	-	-	1,544,943
Performance rights exercised	203,977	(203,977)	-	-	-
Performance rights milestones not achieved	-	(99,000)	-	-	(99,000)
Capital raising cost	(11,703)	-	-	-	(11,703)
Balance at 30 June 2026	**32,656,206**	**8,093,352**	**(30,218,379)**	**5,515**	**10,536,694**

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

Singular Health Group Limited
Consolidated statement of cash flows
For the year ended 30 June 2026

	Note	30 June 2026 $	30 June 2025 $
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		778,865	638,731
Payments to suppliers and employees (inclusive of GST)		(6,487,753)	(3,429,654)
Interest received		386,545	118,847
Government grants received		-	354,539
Interest and other finance costs paid		(4,669)	(23,819)
Deposit received		24,611	-
Net cash (used in) operating activities	**12**	**(5,302,401)**	**(2,341,356)**
Cash flows from investing activities			
Payments for plant and equipment		(143,838)	(29,159)
Payments for term deposits		(7,700,000)	(13,050,000)
Net of cash from disposal of 3DP	6	168,000	57,304
Proceeds from disposal of property, plant and equipment		-	60,000
Proceeds from release of term deposits		13,050,000	-
Net cash from/(used in) investing activities		**5,374,162**	**(12,961,855)**
Cash flows from financing activities			
Proceeds from issue of shares	18	1,694,943	14,715,966
Share issue transaction costs		(11,702)	-
Repayment of borrowings		-	(205,096)
Repayment of lease liabilities		(11,831)	(27,311)
Net cash from financing activities		**1,671,410**	**14,483,559**
Net increase/(decrease) in cash and cash equivalents		1,743,171	(819,652)
Cash and cash equivalents at the beginning of the financial year		628,648	1,455,242
Effects of exchange rate changes on cash and cash equivalents		(9,802)	(6,942)
Cash and cash equivalents at the end of the financial year	**11**	**2,362,017**	**628,648**

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

Note 1. Reporting Entity

The financial statements cover Singular Health Group Limited as a Group consisting of Singular Health Group Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Singular Health Group Limited's functional and presentation currency.
Singular Health Group Limited is a listed public company limited by shares, incorporated and domiciled in Australia.

Note 2. Material accounting policy information

The accounting policies that are material to the Group are set out either in the respective notes or below. The accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated.

(a) Basis of preparation

These general-purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

Historical cost convention

The financial statements have been prepared under the historical cost convention.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in **note 3**.

(b) Going concern

These financial statements have been prepared on a going concern basis, which contemplates the continuity of normal business activities and the realisation of assets and settlement of liabilities in the normal course of business.

As disclosed in the financial report, the Group recorded an operating loss of $6,340,453 (30 June 2025: $6,376,210) and a cash outflow from operating activities of $5,302,401 for the year ended 30 June 2026 (30 June 2025 : $2,341,356). As at 30 June 2026, the Group had cash and cash equivalents of $2,362,017 (30 June 2025: $628,648), term deposits of $7,700,000 (30 June 2025:$13,050,000) and had a working capital surplus of $10,407,131 (30 June 2025: $12,953,756).

The Directors have prepared cash flow forecasts for a period of at least twelve months from the date of signing these financial statements. Having regard to the Group's current cash position, its forecast operating cash flows, and its ability to manage discretionary expenditure, the Directors are satisfied that the Group has sufficient financial resources to meet its obligations as and when they fall due for at least twelve months from the date of this report.

Accordingly, the Directors consider it appropriate to prepare the financial statements on a going concern basis.

(c) Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Singular Health Group Limited ('Company' or 'parent entity') as at 30 June 2026 and the results of all subsidiaries for the year then ended. Singular Health Group Limited and its subsidiaries together are referred to in these financial statements as the 'Group'.

(d) New or amended Accounting Standards and Interpretations adopted

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. These Standards, amendments or interpretations have no material impact on the entity in the current or future reporting periods

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. These Standards, amendments or interpretations are not expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.

Note 3. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Share-based payment transactions
The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either the Monte Carlo or Black-Scholes model taking into account the terms and conditions upon which the instruments were granted detailed within **note 9**. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Revenue from contracts with customers involving sale of goods
When recognising revenue in relation to the sale of goods to customers, the key performance obligation of the Group is considered to be the point of delivery of the goods to the customer, as this is deemed to be the time that the customer obtains control of the promised goods and therefore the benefits of unimpeded access.

Allowance for expected credit losses
The allowance for expected credit losses assessment requires a degree of estimation and judgement. It is based on the lifetime expected credit loss, grouped based on days overdue, and makes assumptions to allocate an overall expected credit loss rate for each group. These assumptions include recent sales experience and historical collection rates.

Significant influence over associate
Management has exercised judgement in determining that the Group has significant influence, but not control, over Singular Imaging Solutions US Inc as at 30 June 2026. In making this assessment, management considered the Group's ownership interest of 33%, representation on the board of directors, participation in policy-making processes and other relevant facts and circumstances.

Accordingly, the investment has been accounted for as an associate using the equity method under AASB 128.

Note 4. Operating segments

Segment information has been prepared in conformity with the accounting policies adopted for preparing and presenting the financial statements of the consolidated Group. The Group has only one primary business segment, which is the provision and development of 3DiCom software medical technology within Australia.

An operating segment is a component of an entity that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity), whose operating results are regularly reviewed by the chief operating decision makers - being the executive management team to make decisions about resources to be allocated to the segment and assess its performance and for which discrete financial information is available. This includes start-up operations which are yet to earn revenues.

Management will also consider other factors in determining operating segments such as the existence of a line manager and the level of segment information presented to the board of directors. Operating segments have been identified based on the information provided to the chief operating decision makers.

Note 5. Revenue

Disaggregation of revenue
The disaggregation of revenue from contracts with customers is as follows:

30 June 2026	Product sales $	Stripe sales $	Total $
Geographical regions			
Australia	-	51,412	51,412
United States of America	1,376,819	-	1,376,819
Total	**1,376,819**	**51,412**	**1,428,231**
Timing of revenue recognition			
Goods transferred at a point in time	-	51,412	51,412
Services rendered over time	1,376,819	-	1,376,819
Total	**1,376,819**	**51,412**	**1,428,231**

30 June 2025	Product sales $	Stripe sales $	Total $
Geographical regions			
Australia	-	54,772	54,772
United States of America	148,297	-	148,297
Total	**148,297**	**54,772**	**203,069**
Timing of revenue recognition			
Goods transferred at a point in time	-	54,772	54,772
Services rendered over time	148,297	-	148,297
Total	**148,297**	**54,772**	**203,069**

Note 6. Discontinued operations

On October 21, 2024, the Company entered into an agreement to sell Singular 3DP Pty Ltd for $250,000. This was later amended on November 25, 2024, to $100,000 through a variation letter and agreement. Additionally, a contingent consideration of $200,000 will be receivable upon the sale of the Titan machine.

The contingent consideration of $200,000 was discounted to its present value using a 7.2% discount rate, resulting in an amount of $187,750, which was recorded as other receivables.

Financial performance information

	30 June 2026 $	30 June 2025 $
Stripe sales	-	32,324
Discontinued debt forgiven	-	9,527
Interest income	-	24
Discontinued total other income	-	9,551
Cost of sales	-	(14,672)
Employee and director benefit expenses	-	(18,390)
Depreciation and amortisation	-	(57,637)
Administration expenses	-	(28,068)
Share-based payments	-	(17,000)
Interest expenses	-	(5,884)
Impairment expenses	-	(56,277)
Discontinued total expenses	**-**	**(197,928)**
Loss before income tax expense	**-**	**(156,053)**
Income tax expense	-	-
Loss after income tax expense	**-**	**(156,053)**
Gain on sale before income tax	-	41,904
Income tax expense	-	-
Gain on sale after income tax expense	-	41,904
Loss after income tax expense from discontinued operations	**-**	**(114,149)**

Cash flow information

	30 June 2026 $	30 June 2025 $
Net cash from operating activities	-	40,814

Note 7. Share of profits of associates and joint ventures accounted for using the equity method

The Group held a 30% equity interest in Singular Imaging Solutions US Inc as at 30 June 2026 and accounted for the investment using the equity method as management concluded that the Group had significant influence but not control over it. The carrying amount of the investment at 30 June 2026 was $nil as no consideration was paid and no material share of profits or losses was recognised during the period.

Note 7. Share of profits of associates and joint ventures accounted for using the equity method (continued)

Accounting policy for Investments in associates

Associates are entities over which the Group has significant influence but not control or joint control. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control.

Investments in associates are accounted for using the equity method and are initially recognised at cost. The carrying amount of the investment is increased or decreased to recognise the Group's share of the associate's profit or loss and other comprehensive income after the date of acquisition.

The Group's share of the associate's profit or loss is recognised in the consolidated statement of profit or loss and other comprehensive income. Distributions received from the associate reduce the carrying amount of the investment.

The carrying amount of investments in associates is assessed for impairment whenever indicators of impairment exist. Where an impairment indicator exists, the Group determines the recoverable amount of the investment and recognises any impairment loss in profit or loss.

Upon disposal or loss of significant influence, the Group derecognises the investment and recognises any resulting gain or loss in profit or loss.

Note 8. Earnings per share

	30 June 2026 $	30 June 2025 $
Loss per share for loss from continuing operations		
Loss after income tax attributable to the owners of Singular Health Group Limited	(6,340,453)	(6,262,061)
	Cents	**Cents**
Basic loss per share	(2.03)	(2.64)
Diluted loss per share	(2.03)	(2.64)

	30 June 2026 $	30 June 2025 $
Loss per share for loss from discontinued operations		
Loss after income tax attributable to the owners of Singular Health Group Limited	-	(114,149)
	Cents	**Cents**
Basic loss per share	-	(0.05)
Diluted loss per share	-	(0.05)

	30 June 2026 $	30 June 2025 $
Loss per share for loss		
Loss after income tax attributable to the owners of Singular Health Group Limited	(6,340,453)	(6,376,210)
	Cents	**Cents**
Basic loss per share	(2.03)	(2.69)
Diluted loss per share	(2.03)	(2.69)

Note 8. Earnings per share (continued)

	Number	Number
Weighted average number of ordinary shares		
Weighted average number of ordinary shares used in calculating basic earnings per share	312,538,103	237,045,208
Weighted average number of ordinary shares used in calculating diluted earnings per share	312,538,103	237,045,208

Note 9. Share-based payments

	Note	30 June 2026 $	30 June 2025 $
Share-based payments from continuing operations		2,089,670	3,265,133
Share-based payment from discontinuing operations	6	-	17,000
		2,089,670	3,282,133

Shares
During the year ended 30 June 2026, **$849,552** share-based payment expense was recognised as a result of shares issued.

On 10 September 2025, the Company issued 2,785,416 ordinary shares in consideration for consulting services provided by Marin and sons. In accordance with AASB 2 *Share-based Payment*, the shares were measured at their fair value at the grant date (10 September 2025), being the market price of $0.305 per share.

Options
A share option plan has been established by the Group and approved by shareholders at a general meeting, which grant options over ordinary shares in the Company. The options are issued for nil consideration and are granted in accordance with performance guidelines established by the Company.

Set out below are summaries of options granted under the plan:

	Number of options 30 June 2026	Weighted average exercise price 30 June 2026	Number of options 30 June 2025	Weighted average exercise price 30 June 2025
Outstanding at the beginning of the financial year	76,143,000	$0.225	59,580,000	$0.140
Granted	6,000,000	$0.550	42,325,000	$0.285
Exercised	(1,666,559)	$0.150	(5,212,000)	$0.111
Expired	(10,263,441)	$0.371	(20,550,000)	$0.298
Outstanding at the end of the financial year	70,213,000	$0.239	76,143,000	$0.226

Note 9. Share-based payments (continued)

30 June 2026

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
23/11/2021	20/12/2025	$0.300	20,000	-	-	(20,000)	-
23/11/2021	20/12/2025	$0.300	300,000	-	-	(300,000)	-
23/11/2021	20/12/2025	$0.300	40,000	-	-	(40,000)	-
23/11/2021	20/12/2025	$0.300	1,670,000	-	-	(1,670,000)	-
28/11/2022	23/12/2025	$0.400	5,000,000	-	-	(5,000,000)	-
16/06/2023	26/06/2026	$0.100	4,000,000	-	(766,559)	(3,233,441)	-
10/11/2023	11/11/2027	$0.008	18,250,000	-	-	-	18,250,000
27/06/2024	26/06/2027	$0.150	4,538,000	-	(900,000)	-	3,638,000
20/11/2024	19/02/2028	$0.150	6,325,000	-	-	-	6,325,000
28/11/2024	28/11/2027	$0.150	9,000,000	-	-	-	9,000,000
19/03/2025	15/04/2029	$0.250	10,000,000	-	-	-	10,000,000
19/03/2025	15/04/2028	$0.250	2,000,000	-	-	-	2,000,000
19/03/2025	15/04/2028	$0.250	5,000,000	-	-	-	5,000,000
26/06/2025	26/06/2028	$0.550	10,000,000	-	-	-	10,000,000
19/11/2025	30/09/2029	$0.550	-	6,000,000	-	-	6,000,000
			76,143,000	6,000,000	(1,666,559)	(10,263,441)	70,213,000
Weighted average exercise price			$0.226	$0.550	$0.150	$0.371	$0.239

30 June 2025

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
12/02/2021	12/02/2025	$0.300	19,250,000	-	-	(19,250,000)	-
23/11/2021	20/12/2025	$0.300	20,000	-	-	-	20,000
23/11/2021	20/12/2025	$0.300	300,000	-	-	-	300,000
23/11/2021	20/12/2025	$0.300	40,000	-	-	-	40,000
23/11/2021	12/02/2025	$0.300	250,000	-	-	(250,000)	-
23/11/2021	12/02/2025	$0.300	250,000	-	-	(250,000)	-
23/11/2021	20/12/2025	$0.300	1,670,000	-	-	-	1,670,000
03/08/2022	19/08/2024	$0.240	800,000	-	-	(800,000)	-
28/11/2022	23/12/2025	$0.400	5,000,000	-	-	-	5,000,000
16/06/2023	26/06/2026	$0.100	500,000	-	-	-	500,000
16/06/2023	26/06/2026	$0.100	3,500,000	-	-	-	3,500,000
10/11/2023	11/11/2027	$0.008	19,500,000	-	(1,250,000)	-	18,250,000
27/06/2024	26/06/2027	$0.150	8,500,000	-	(3,962,000)	-	4,538,000
20/11/2024	19/02/2028	$0.150	-	6,325,000	-	-	6,325,000
28/11/2024	28/11/2027	$0.150	-	9,000,000	-	-	9,000,000
19/03/2025	15/04/2029	$0.250	-	10,000,000	-	-	10,000,000
19/03/2025	15/04/2028	$0.250	-	2,000,000	-	-	2,000,000
19/03/2025	15/04/2028	$0.250	-	5,000,000	-	-	5,000,000
26/06/2025	26/06/2028	$0.550	-	10,000,000	-	-	10,000,000
			59,580,000	42,325,000	(5,212,000)	(20,550,000)	76,143,000
Weighted average exercise price			$0.140	$0.280	$0.111	$0.298	$0.226

Note 9. Share-based payments (continued)

Set out below are the options exercisable at the end of the financial year:

Grant date	Expiry date	30 June 2026 Number
10/11/2023	11/11/2027	18,250,000
27/06/2024	26/06/2027	3,638,000
20/11/2024	19/02/2028	6,325,000
28/11/2024	28/11/2027	9,000,000
19/03/2025	15/04/2029	10,000,000
19/03/2025	15/04/2028	2,000,000
19/03/2025	15/04/2028	5,000,000
26/06/2025	26/06/2028	10,000,000
19/11/2025	30/09/2029	3,000,000
		67,213,000

The weighted average share price during the financial 30 June 2026 was $0.2769 (30 June 2025: $0.191).

The weighted average remaining contractual life of options outstanding at the end of the financial 30 June 2026 was 2 years (30 June 2025: 2.19 years).

Valuation of options granted during the year ended 30 June 2026 is as set out below:

During the year ended 30 June 2026, **$1,278,308** (30 June 2025: $2,213,993) comprising $686,898 relating to options granted and vested during the current financial year, and $591,409 relating to options granted in prior years that vested during the current financial year.
Following approval at the Annual General Meeting held on 19 November 2025 under shareholder-approved resolution in accordance with ASX Listing Rule 10.14, the Director options are being issued to Mr Denning Chong as part of his Incentive Package for the period from 1 July 2025 in respect of his role as CEO and Managing Director of the Group.

Recipient	Class of securities	Grant date	No. of securities	Exercise price	Expiry date	Vesting Conditions
Denning Chong	Unlisted Options Tranche A	19-Nov-25	3,000,000	$0.55	5 pm (WST) on 30 November 2029	- Company achieves a 20-day VWAP of $0.65; and - Continuous employment or engagement to 30 June 2026
Denning Chong	Unlisted Options Tranche B	19-Nov-25	3,000,000	$0.55	5 pm (WST) on 30 November 2029	- Company achieves a 20-day VWAP of $0.80; and - Continuous employment or engagement to 30 June 2027.

Note 9. Share-based payments (continued)

	Tranche A	Tranche B
Methodology	Monte-Carlo	Monte-Carlo
Iterations	100,000	100,000
Grant date	19 November 2025	19 November 2025
Expiry date	30 November 2029	30 November 2029
Share price at grant date	$0.29	$0.29
VWAP hurdle	$0.65	$0.80
Exercise price	$0.55	$0.55
Risk-free rate (%)	3.826%	3.826%
Volatility (%)*	95%	95%
Dividend yield (%)	nil	nil
Fair value per option	$0.1662	$0.1655
Number	3,000,000	3,000,000
Total fair value	$498,600	$496,500

**The historical volatility of Singular shares over the 4-year period to 19 November 2025, based on daily closing prices, was 100.31%. The rolling annual volatility (based on prior year weekly closing prices) of Singular shares to 19 November 2025 is shown below. The average volatility over this period was 94.42%. Based on the above analysis we used an expected volatility factor of 95% in our valuations.*

Valuation of options granted during the year ended 30 June 2025 as below:

For the 32,325,000 options granted during 30 June 2025, the Black-Scholes valuation model inputs used to determine the fair value at the grant date and no other conditions attached, are as follows:

Grant date	Expiry date	Share price at grant date	Exercise price	Expected volatility[1]	Dividend yield	Risk-free interest rate	Fair value at grant date
20/11/2024	19/02/2028	$0.100	$0.150	100.00%	-	3.93%	$0.0580
28/11/2024	28/11/2027	$0.091	$0.150	100.00%	-	3.97%	$0.0489
19/03/2025	15/04/2028	$0.230	$0.250	100.00%	-	3.79%	$0.1480
19/03/2025	15/04/2028	$0.175	$0.250	100.00%	-	3.84%	$0.1003
26/06/2025	26/06/2028	$0.365	$0.550	100.00%	-	3.23%	$0.2014

[1]*The volatility % was based on the Company's historical share price over the 4 year-period.*

Note 9. Share-based payments (continued)

On 19 March 2025, the shareholder approved at the General Meeting to issue 10,000,000 incentive options to Mr. Denning Chong as part of long-term incentive package in respect of his role as Chief Executive Officer and Managing Director for the period from 1 July 2024. The options were valued using Monte-Carlo simulation methodology as the options were subject to market based and service based vesting conditions. The details are as below:

	Tranche 1	Tranche 2	Tranche 3	Tranche 4
Methodology	Monte Carlo	Monte Carlo	Monte Carlo	Monte Carlo
Iterations	100,000	100,000	100,000	100,000
Grant date	19 March 2025	19 March 2025	19 March 2025	19 March 2025
Expiry date	15 April 2029	15 April 2029	15 April 2029	15 April 2029
Share price at grant date ($)	0.235	0.235	0.235	0.235
Exercise price ($)	0.25	0.25	0.25	0.25
VWAP hurdle ($)	0.25	0.25	0.25	0.25
Risk-free rate (%)	3.856	3.856	3.856	3.856
Volatility (%)1	100	100	100	100
Dividend yield (%)	nil	nil	nil	nil
Fair value per option	0.1578	0.1576	0.1571	0.1560
Number	2,500,000	2,500,000	2,500,000	2,500,000
Total fair value ($)	394,473	394,056	392,718	390,115
Vesting Conditions	Singular shares achieving a 14-day VWAP of $0.25	Singular shares achieving a 14-day VWAP of $0.35	Singular shares achieving a 14-day VWAP of $0.45	Singular shares achieving a 14-day VWAP of $0.55

Performance rights

During the year ended 30 June 2026, **$60,810** (30 June 2025: $nil) share-based payment expense recognised as a result of performance rights issued from prior year vested and **$99,000** (30 June 2025: $1,000,000) was reversed in share-based payment expense as milestone was not achieved.

Set out below are summaries of performance rights granted under the Employee Share Option Plan:

	Number of rights 30 June 2026	Weighted average exercise price 30 June 2026	Number of rights 30 June 2025	Weighted average exercise price 30 June 2025
Outstanding at the beginning of the financial year	15,450,000	$0.000	29,600,000	$0.000
Granted	-	$0.000	10,000,000	$0.000
Exercised	(5,450,000)	$0.000	(5,625,000)	$0.000
Expired	-	$0.000	(18,525,000)	$0.000
Outstanding at the end of the financial year	10,000,000	$0.000	15,450,000	$0.000

30 June 2026

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
12/02/2021	31/12/2024	$0.000	450,000	-	(450,000)	-	-
12/02/2021	31/12/2024	$0.000	500,000	-	(500,000)	-	-
10/11/2023	10/11/2027	$0.000	4,500,000	-	(4,500,000)	-	-
26/06/2024	30/06/2028	$0.000	10,000,000	-	-	-	10,000,000
			15,450,000	-	(5,450,000)	-	10,000,000

Note 9. Share-based payments (continued)

30 June 2025

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
12/02/2021	31/12/2024	$0.000	5,000,000	-	-	(5,000,000)	-
28/11/2022	29/11/2025	$0.000	2,000,000	-	(2,000,000)	-	-
14/12/2022	14/12/2025	$0.000	2,600,000	-	(1,500,000)	(1,100,000)	-
28/11/2022	29/11/2025	$0.000	1,000,000	-	(1,000,000)	-	-
14/12/2022	14/12/2025	$0.000	1,300,000	-	(750,000)	(550,000)	-
20/09/2023	20/09/2025	$0.000	4,500,000	-	-	-	4,500,000
10/11/2023	10/11/2027	$0.000	1,600,000	-	(375,000)	(775,000)	450,000
10/11/2023	10/11/2027	$0.000	11,600,000	-	-	(11,100,000)	500,000
26/06/2024	30/06/2028	$0.000	-	10,000,000	-	-	10,000,000
			29,600,000	10,000,000	(5,625,000)	(18,525,000)	15,450,000

The weighted average remaining contractual life of performance rights outstanding at the end of the financial year was 2 years (30 June 2025: 2 years).

For the 10,000,000 performance rights granted during the last financial year, the valuation model inputs used to determine the fair value at the grant date, are as follows:

	Tranche 1	Tranche 2	Tranche 3	Tranche 4
Methodology	Monte Carlo	Monte Carlo	Monte Carlo	Monte Carlo
Iterations	100,000	100,000	100,000	100,000
Grant date	19 March 2025	19 March 2025	19 March 2025	19 March 2025
Expiry date	15 April 2029	15 April 2029	15 April 2029	15 April 2029
Share price at grant date ($)	0.235	0.235	0.235	0.235
Exercise price ($)	0.25	0.25	0.25	0.25
VWAP hurdle ($)	0.25	0.25	0.25	0.25
Risk-free rate (%)	3.856	3.856	3.856	3.856
Volatility (%)1	100	100	100	100
Dividend yield (%)	nil	nil	nil	nil
Fair value per option	0.1578	0.1576	0.1571	0.1560
Number	2,500,000	2,500,000	2,500,000	2,500,000
Total fair value ($)	394,473	394,056	392,718	390,115
Vesting Conditions	Singular shares achieving a 14-day VWAP of $0.25	Singular shares achieving a 14-day VWAP of $0.35	Singular shares achieving a 14-day VWAP of $0.45	Singular shares achieving a 14-day VWAP of $0.55

Accounting policy for share-based payments
Equity-settled share-based compensation benefits are provided to employees and consultants in exchange for their services.

Note 9. Share-based payments (continued)

The cost of equity-settled transactions are measured at fair value on grant date. Fair value for employees and consultants are independently determined using either Monte-Carlo, Black-Scholes pricing model.

For Black-Scholes valuation model it takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the Group receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

For Monte-Carlo simulation, it is a stochastic model that uses random sampling to simulate thousands of possible future paths for the share price. Especially useful for complex vesting conditions, such as market-based performance targets (e.g., share price reaching a certain level). It can incorporate:
- Time-varying volatility
- Correlations between multiple variables
- Early exercise behavior
- More flexible than Black-Scholes but computationally intensive.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

Note 10. Income tax

	30 June 2026 $	30 June 2025 $
Income tax expense		
Current tax	-	-
Deferred tax - origination and reversal of temporary differences	-	-
Aggregate income tax expense	-	-
Numerical reconciliation of income tax expense and tax at the statutory rate		
Loss before income tax expense from continuing operations	(6,340,453)	(6,262,061)
Loss before income tax expense from discontinued operations	-	(114,149)
	(6,340,453)	(6,376,210)
Tax at the statutory tax rate of 25%	(1,585,113)	(1,594,053)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:		
Non-allowable items	574,189	826,953
Revenue losses and other deferred tax balances not recognised	1,128,809	885,976
	117,885	118,876
Less tax effect of:		
R&D refundable tax offset	(117,885)	(88,635)
Other non-assessable income	-	(30,241)
Income tax expense	**-**	**-**

Note 10. Income tax (continued)

	30 June 2026 $	30 June 2025 $
Deferred tax assets not recognised at 25% (30 June 2025: 25%)		
Deferred tax assets not recognised comprises temporary differences attributable to:		
Allowance for expected credit losses	-	1,852
Provision for obsolescence	-	17,655
Leases	27,491	2,489
Provision and accruals	60,877	39,077
Capital losses	-	473,059
Plant and equipment	818,477	90,473
Transaction costs arising on shares issued	59,699	83,957
Other	5,295	9,680
Tax losses	1,883,033	3,055,142
Deferred tax liabilities not recognised comprises temporary differences attributable to:		
Prepayments	(20,888)	(15,022)
Plant and equipment under lease	(22,495)	(308)
Accrued interest	(20,780)	(6,392)
Other	(912)	-
Non-recognition of deferred tax liabilities/losses	**2,789,797**	**3,751,662**

The above potential tax benefit, which excludes tax losses, for deductible temporary differences has not been recognised in the statement of financial position as the recovery of this benefit is uncertain.

Note 11. Cash and cash equivalents

	30 June 2026 $	30 June 2025 $
Current assets		
Cash at bank	2,362,017	628,648

Note 12. Cash flow information

Reconciliation of loss after income tax to net cash (used in) operating activities

	30 June 2026 $	30 June 2025 $
Loss after income tax expense for the year	(6,340,453)	(6,376,210)
Adjustments for:		
Depreciation and amortisation	80,937	129,657
Write off of receivables	19,750	-
Net profit on disposal of 3DP	-	41,904
Share-based payments	2,089,670	3,265,133
Foreign exchange differences	18,012	9,541
Interest expense on leases	-	13,357
Non-cash director fees in lieu	-	78,604
Capital allowance on receivables	(1,233)	1,233
Change in operating assets and liabilities:		
Increase in trade and other receivables	(627,552)	(127,852)
Increase in prepayments	(24,945)	(11,650)
(Decrease)/Increase in trade and other payables	(131,562)	191,955
(Decrease)/Increase in contract liabilities	(464,721)	460,190
Increase/(decrease) in other provisions	79,696	(17,218)
Net cash (used in) operating activities	(5,302,401)	(2,341,356)

Non-cash investing and financing activities

	30 June 2026 $	30 June 2025 $
Additions to the right-of-use assets	89,979	-
Shares issued under employee share plan	-	274,604
Shares issued to consultant	849,552	-
	939,531	274,604

Note 13. Trade and other receivables

	30 June 2026 $	30 June 2025 $
Current assets		
Trade receivables	241,758	62,270
Less: Allowance for expected credit losses	-	(1,233)
	241,758	61,037
Other receivables*	-	95,896
R&D Receivable	471,540	-
Bond receivable	-	29,618
	471,540	125,514
Interest receivable	83,120	25,566
GST receivable	62,942	40,759
	859,360	**252,876**
Non-current assets		
Other receivables*	-	91,854
	859,360	344,730

* Other receivables include contingent consideration of $200,000 related to the proceeds from sale of Singular 3DP Pty Ltd will become receivable upon the sale of the Titan machine by 3DP. This amount has been discounted to its present value of $187,750 using a discount rate of 7.2%, based on a payment maturity of 24 months. Of this, $91,854 has been classified as a non-current in the prior year.

During the year, the Company entered into a Deed of Settlement and Release in relation to the Share Sale Agreement, pursuant to which the parties agreed to fully and final settle the outstanding balance of $175,000 (inclusive of principal and accrued interest) for a reduced payment of $119,000.

Allowance for expected credit losses
The Group has recognised a loss of $nil (30 June 2025: $50,242) in profit or loss in respect of the expected credit losses for the year ended 30 June 2026.

The ageing of the receivables and allowance for expected credit losses provided for above are as follows:

	Expected credit loss rate		Carrying amount		Allowance for expected credit losses	
	30 June 2026 %	30 June 2025 %	30 June 2026 $	30 June 2025 $	30 June 2026 $	30 June 2025 $
0 to 3 months overdue	-	-	142,130	38,148	-	-
3 to 6 months overdue	-	-	99,628	22,888	-	-
Over 6 months overdue	-	100%	-	1,233	-	1,233
			241,758	62,269	-	1,233

Note 13. Trade and other receivables (continued)

Movements in the allowance for expected credit losses are as follows:

	30 June 2026 $	30 June 2025 $
Opening balance	1,233	50,242
Additional provisions recognised	-	1,233
Receivables written off during the year as uncollectable	(1,233)	(50,242)
Closing balance	**-**	**1,233**

Note 14. Financial assets

	30 June 2026 $	30 June 2025 $
Current assets		
Term deposits	7,700,000	13,050,000

Refer to note 21 for further information on fair value measurement.

Term deposits with original maturities exceeding three months are classified as financial investments rather than cash equivalents. These deposits are not held for the purpose of meeting short-term cash commitments and are subject to a higher risk of changes in value due to interest rate fluctuation or withdrawal penalties. Accordingly, they are presented as part of financial assets in the statement of financial position and reported under investing activities in the statement of cash flows.

Note 15. Right-of-use assets

	30 June 2026 $	30 June 2025 $
Non-current assets		
Office building and car park - right-of-use	116,565	-
Less: Accumulated depreciation	(26,586)	-
	89,979	-

Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	Building and Car park $	Total $
Balance at 1 July 2024	-	-
Balance at 30 June 2025	-	-
Additions	116,565	116,565
Depreciation expense	(26,586)	(26,586)
Balance at 30 June 2026	**89,979**	**89,979**

Note 15. Right-of-use assets (continued)

Accounting policy for right-of-use assets

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Group expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

Right-of-use assets that meet the definition of investment property are measured at fair value where the Group has adopted a fair value measurement basis for investment property assets.

The Group has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

Note 16. Contract liabilities

	30 June 2026 $	30 June 2025 $
Current liabilities		
Contract liabilities	-	464,721

Reconciliation

Reconciliation of the written down values at the beginning and end of the current and previous financial year are set out below:

Opening balance	464,721	-
Payments received in advance	-	464,721
Transfer to revenue - performance obligations satisfied	(464,721)	-
Closing balance	-	464,721

Unsatisfied performance obligations

The aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied at the end of the reporting period was $nil as at 30 June 2026 ($464,721 as at 30 June 2025) and is expected to be recognised as revenue in future periods as follows:

	30 June 2026 $	30 June 2025 $
Within 6 months	-	232,360
6 to 12 months	-	232,361
	-	464,721

Note 17. Lease liabilities

	30 June 2026 $	30 June 2025 $
Current liabilities		
Lease liability	16,097	-
Non-current liabilities		
Lease liability	93,866	-
	109,963	-

Reconciliation of lease liabilities		
Addition	116,565	-
Interest	9,898	-
Payment	(16,500)	-
	109,963	-

During the year, the Group entered into a new office lease for premises located at 661 Newcastle Street, Leederville, WA, commencing 1 August 2025 for an initial two-year term with a two-year renewal option. In accordance with AASB 16, the Group recognised a right-of-use asset and corresponding lease liability on commencement of the lease.

The lease includes a rent-free period until 31 July 2026, with annual fixed rent increases of 10% thereafter.

Refer to **note 20** for further information on financial instruments.

Accounting policy for lease liabilities
Lease liabilities are measured at the present value of future lease payments and the related right-of-use asset is depreciated over the lease term.

Note 18. Issued capital

	30 June 2026 Shares	30 June 2025 Shares	30 June 2026 $	30 June 2025 $
Ordinary shares - fully paid	323,773,117	301,692,227	36,796,044	34,047,572
Capital raising cost	-	-	(4,139,838)	(4,128,136)
	323,773,117	301,692,227	32,656,206	29,919,436

Movements in ordinary share capital

Details	Date	Shares	Issue price	$
Balance	01-Jul-24	195,603,055		16,430,777
Issue of shares in respect of capital raising	25-Jul-24	6,666,667	$0.150	1,000,000
Issue of shares to Director in lieu of Director fees	25-Jul-24	714,582	$0.110	78,604
Issue of shares on exercise of performance rights	25-Jul-24	2,775,000	$0.000	102,726
Issue of shares to ex-Director of 3DP	25-Jul-24	1,000,000	$0.099	99,000
Minor settlement difference to ex-Director of 3DP	28-Nov-24	200,000	$0.000	17,000
Issue of shares in respect of capital raising	28-Nov-24	35,555,557	$0.090	3,200,000
Issue of shares on exercise of options	30-Dec-24	4,200,001	$0.100	420,000
Issue of shares on exercise of performance rights	30-Dec-24	500,000	$0.000	17,985
Issue of shares on exercise of options	16-Jan-25	1,615,911	$0.100	161,591

Note 18. Issued capital (continued)

Details	Date	Shares	Issue price	$
Issue of shares on exercise of performance rights	20-Jan-25	8,100,000	$0.100	560,268
Issue of shares on exercise of options	03-Feb-25	1,000,000	$0.150	150,000
Issue of shares on exercise of performance rights	03-Feb-25	400,000	$0.230	48,768
Issue of shares on exercise of options	04-Mar-25	1,250,000	$0.080	100,000
Issue of shares on exercise of options	07-Mar-25	618,181	$0.100	61,818
Issue of capital raising shares to PNS	26-Mar-25	5,555,556	$0.090	500,000
Issue of shares on exercise of options	27-Mar-25	50,000	$0.150	7,500
Issue of shares on exercise of options	16-Apr-25	1,030,000	$0.150	154,500
Issue of shares on exercise of options	06-May-25	794,985	$0.100	79,499
Issue of shares on exercise of options	06-May-25	50,000	$0.150	7,500
Issue of shares on exercise of options	30-May-25	152,728	$0.100	15,273
Issue of shares on exercise of options	30-May-25	1,025,000	$0.150	153,750
Issue of shares on exercise of performance rights	30-May-25	3,750,000	$0.150	273,577
Issue of shares to consultants	30-May-25	250,000	$0.320	80,000
Issue of capital raising shares to Marin & Sons	30-May-25	4,831,250	$0.160	773,000
Issue of shares in respect of capital raising	26-Jun-25	22,428,572	$0.350	7,850,000
Issue of shares on exercise of options	26-Jun-25	768,182	$0.100	76,818
Issue of shares on exercise of options	26-Jun-25	807,000	$0.150	121,050
Capital raising cost		-	$0.000	(2,621,568)
Balance	**30 June 2025**	**301,692,227**		**29,919,436**

Details	Date	Shares	Issue price	$
Balance	01-Jul-25	301,692,227		29,919,436
Issue of shares from exercise of options (DC)	08-Aug-25	1,818,181	$0.100	181,818
Issue of shares from exercise of performance rights (MM, EC and AM)	08-Aug-25	950,000	$0.000	32,977
Issue of Shares from vested Performance Rights (Consultant - Marin & Son)	10-Sep-25	4,500,000	$0.000	171,000
Issue of shares from exercise of options	10-Sep-25	381,818	$0.100	38,182
Issue of shares to consultant (Consultant - Marin & Son)	10-Sep-25	2,785,416	$0.310	849,552
Issue of shares to PNS (announced on 19 June 25)	10-Sep-25	428,571	$0.350	150,000
Issue of shares from exercise of options	20-Nov-25	509,091	$0.100	50,909
Issue of shares from exercise of options	09-Dec-25	900,000	$0.150	135,000
Issue of shares from exercise of options (12 months escrow)	19-Jan-26	1,720,000	$0.200	344,000
Issue of shares from exercise of options	09-Apr-26	272,728	$0.100	27,273
Issue of shares from exercise of options	01-May-26	363,636	$0.100	36,364
Issue of shares from exercise of options	14-May-26	420,000	$0.100	42,000
Issue of shares from exercise of options	22-Jun-26	3,772,727	$0.100	377,275
Issue of shares from exercise of options	22-Jun-26	687,500	$0.080	55,000
Issue of shares from exercise of options	26-Jun-2026	2,571,222	$0.100	257,122
Capital raising cost		-		(11,702)
Balance	**30 June 2026**	**323,773,117**		**32,656,206**

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

Capital risk management

The Group's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Note 18. Issued capital (continued)

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

The Group would look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current Company's share price at the time of the investment. The Group is not actively pursuing additional investments in the short term as it continues to integrate and grow its existing businesses in order to maximise synergies.

The Group is subject to certain financing arrangements covenants and meeting these is given priority in all capital risk management decisions. There have been no events of default on the financing arrangements during the financial year.

The capital risk management policy remains unchanged from the 30 June 2025 Annual Report.

Note 19. Reserves

	30 June 2026 $	30 June 2025 $
Foreign currency translation reserve	5,514	(2,165)
Share-based payments reserve	8,093,353	7,057,212
	8,098,867	7,055,047

Movements in reserves

Movements in each class of reserve during the current and previous financial year are set out below:

Reconciliation of movement in performance rights

	Date	No. of performance rights	$
Balance at 1 July 2024		29,600,000	1,689,247
Performance rights granted to Directors	25-Jul-24	10,000,000	549,656
Conversion of performance rights to ordinary shares	25-Jul-24	(2,775,000)	(102,726)
Performance rights expired	19-Aug-24	(925,000)	-
Performance rights expired	11-Oct-24	(2,700,000)	-
Conversion of performance rights to ordinary shares	30-Dec-24	(500,000)	(17,985)
Performance rights expired	31-Dec-24	(5,000,000)	(1,000,000)
Conversion of performance rights to ordinary shares	20-Jan-25	(8,100,000)	(560,268)
Conversion of performance rights to ordinary shares	03-Feb-25	(400,000)	(48,768)
Conversion of performance rights to ordinary shares	30-May25	(3,750,000)	(273,577)
Vesting of employee performance rights	30-Jun-25	-	861,987
Balance at 30 June 2025		**15,450,000**	**1,097,566**
Conversion of performance rights to ordinary shares	8-Aug-25	(950,000)	(32,976)
Conversion of performance rights to ordinary shares	10-Sep-25	(4,500,000)	(171,000)
Performance milestone not achieved	30-Jun-26	-	(99,000)
Vesting of employee performance rights	30-Jun-26	-	60,810
Balance at 30 June 2026		**10,000,000**	**855,400**

Note 19. Reserves (continued)

Reconciliation of movement in options

	Date	No. of options	$
Options lapsed	19-Aug-24	(1,300,000)	(24,467)
Issue of options in respect of capital raise	28-Nov-24	9,000,000	440,500
Issue of options to broker (cash consideration received)	28-Nov-24	-	9,000
Issue of shares from exercise of options	30-Dec-24	(4,200,001)	-
Issue of shares from exercise of options	16-Jan-25	(1,615,911)	-
Issue of shares from exercise of options	03-Feb-25	(1,000,000)	-
Options expired	10-Feb-25	(19,250,000)	(2,377,373)
Issue of options to employees	19-Feb-25	6,325,000	231,284
Issue of shares from exercise of options	04-Mar-25	(1,250,000)	-
Issue of shares from exercise of options	07-Mar-25	(618,181)	-
Issue of shares from exercise of options	27-Mar-25	(50,000)	-
Issue of options to Directors and consultant	15-Apr-25	17,000,000	1,542,208
Issue of shares from exercise of options	16-Apr-25	(1,030,000)	-
Issue of shares from exercise of options	06-May-25	(844,985)	-
Issue of shares from exercise of options	30-May-25	(1,177,728)	-
Issue of shares from exercise of options	26-Jun-25	(1,575,182)	-
Issue of options to broker in respect to capital raise	26-Jun-25	10,000,000	2,014,148
Issue of options to broker (cash consideration received)	26-Jun-25	-	1,000
Balance at 30 June 2025		**96,751,298**	**5,959,646**
Issue of shares from exercise of options	08-Aug-25	(1,818,181)	-
Issue of shares from exercise of options	10-Sep-25	(381,818)	-
Issue of shares from exercise of options	20-Nov-25	(509,091)	-
Issue of shares from exercise of options	09-Dec-25	(900,000)	-
Issue of options to Director	18-Dec-25	6,000,000	686,898
Expiry of options	20-Dec-25	(2,030,000)	-
Expiry of options	23-Dec-25	(5,000,000)	-
Issue of shares from exercise of options (12 months escrow)	19-Jan-26	(1,720,000)	-
Issue of shares from exercise of options	09-Apr-26	(272,728)	-
Issue of shares from exercise of options	01-May-26	(363,636)	-
Issue of shares from exercise of options	14-May-26	(420,000)	-
Issue of shares from exercise of options	22-Jun-26	(4,460,227)	-
Issue of shares from exercise of options	26-Jun-26	(2,571,222)	-
Expiry of options	26-Jun-26	(3,233,441)	-
Vesting of prior period options	30-Jun-26	-	591,409
Balance 30 June 2026		**79,070,954**	**7,237,953**

Accounting policy for reserves

Share-based payments reserve

The reserve is used to recognise the value of equity benefits provided to employees and Directors as part of their remuneration, and other parties as part of their compensation for services.

Foreign currency reserve

The reserve is used to recognise exchange differences arising from the translation of the financial statements of foreign operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net investments in foreign operations.

Note 20. Financial instruments

Financial risk management objectives
The Group's activities expose it to a variety of financial risks: market risk (including foreign currency risk, price risk and interest rate risk), credit risk and liquidity risk. The Group's overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the financial performance of the Group. The Group does not use derivative financial instruments; however, the Group uses different methods to measure different types of risk to which it is exposed. These methods include sensitivity analysis in the case of interest rate, and other price risks and aging analysis for credit risk.

Risk management is carried out by Board of Directors ('the Board') with assistance from suitably qualified external and internal advisors. These policies include identification and analysis of the risk exposure of the Group and appropriate procedures, controls and risk limits. Finance identifies, evaluates within the Group's operating units. Finance reports to the Board on a quarterly basis and the Board provides written principles for overall risk management and further policies evolve commensurate with the evolution and growth of the Group.

Market risk
Foreign currency risk
The Group is exposed to foreign currency risk from United States dollar (USD) cash holdings, customer receivables and supplier payments. USD receipts and USD payments provide a natural hedge to the extent that their amounts and timing are matched. The Group remains exposed where USD is purchased or received before it is required, where inflows and outflows differ, or where settlement timing is mismatched. Exchange-rate movements may therefore affect the Australian-dollar value of monetary assets and liabilities, profit or loss, cash flows and operating margins. The Group monitors forecast and recognised USD exposures and retains USD receipts for expected USD payments.

		AUD strengthened			AUD weakened	
30 June 2026	**% change**	**Effect on profit before tax**	**Effect on equity**	**% change**	**Effect on profit before tax**	**Effect on equity**
USD Monetary assets	10%	72,729	72,729	(10%)	(72,729)	(72,729)

Price risk
The Group is not exposed to any significant price risk.

Interest rate risk
The Group's main interest rate risk arises from cash at bank with variable interest rates and term deposits at fixed interest rate at maturity date.

Credit risk
Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Group. The Group has a strict code of credit, including obtaining agency credit information, confirming references and setting appropriate credit limits as a means of mitigating the risk of financial loss from defaults. The maximum exposure to credit risk at the reporting date to recognised financial assets is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the statement of financial position and notes to the financial statements. The Group does not hold any collateral.

Generally, trade receivables and other receivables are written off when there is no reasonable expectation of recovery. Indicators of this include the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for a period greater than 1 year.

The Group held cash and cash equivalents with bank which is rated AA- to AA+.

Note 20. Financial instruments (continued)

	30 June 2026 $	30 June 2025 $
Cash and cash equivalents	2,362,017	628,648
Term deposits	7,700,000	13,050,000
	10,062,017	13,678,648

The Group considers that its cash and cash equivalents have low credit risk based on the external credit ratings of the counterparties.

Allowance for expected credit losses

The Group has recognised a discontinued loss of $nil (30 June 2025: $17,675) in profit or loss in respect of the expected credit losses for the year ended 30 June 2026.

Liquidity risk

Vigilant liquidity risk management requires the Group to maintain sufficient liquid assets (mainly cash and cash equivalents) and available borrowing facilities to be able to pay debts as and when they become due and payable.

The Group manages liquidity risk by maintaining adequate cash reserves and available borrowing facilities by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities.

Remaining contractual maturities

Prudent liquidity risk management implies maintaining sufficient cash and marketable securities, the availability of funding through an adequate amount of committed credit facilities and the ability to close out market positions. The Group manages liquidity risk by continuously monitoring forecast and actual cash flows and matching the maturity profits of financial assets and liabilities. As at reporting date the Group had sufficient cash reserves to meet its requirements. The Group therefore had no credit standby facilities or arrangements for further funding in place.

The financial liabilities of the Group at reporting date were trade and other payables incurred in the normal course of the business. Trade and other payables were non-interest bearing and were due within the normal 30-60 days terms of creditor payments. Borrowings have fixed terms of repayment and interest payable. The Group does not consider these liabilities to be material to the Group and have therefore not undertaken any further analysis of risk exposure.

The following tables detail the Group's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position.

30 June 2026	Weighted average interest rate %	Less than 6 months $	1 year or less $	Between 1 and 2 years $	Between 2 and 5 years $	Over 5 years $	Remaining contractual maturities $
Non-derivatives							
Non-interest bearing							
Trade payables	-	149,025	-	-	-	-	149,025
Other payables	-	267,815	-	-	-	-	267,815
Interest-bearing - fixed rate							
Lease liability	10.00%	18,178	40,945	69,288	-	-	128,411
Total non-derivatives		435,018	40,945	69,288	-	-	545,251

Note 20. Financial instruments (continued)

30 June 2025	Weighted average interest rate %	Less than 6 months $	1 year or less $	Between 1 and 2 years $	Between 2 and 5 years $	Over 5 years $	Remaining contractual maturities $
Non-derivatives							
Non-interest bearing							
Trade payables	-	259,493	-	-	-	-	259,493
Other payables	-	294,068	-	-	-	-	294,068
Total non-derivatives		553,561	-	-	-	-	553,561

The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

Fair value of financial instruments

Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value due to their short-term in nature.

Note 21. Fair value measurement

The carrying amounts of trade and other receivables and trade and other payables are assumed to approximate their fair values due to their short-term nature.

The fair value of financial liabilities is estimated by discounting the remaining contractual maturities at the current market interest rate that is available for similar financial liabilities.

Note 22. Key management personnel disclosures

Directors

The following persons were Directors of Singular Health Group Limited during the financial year:

Howard Digby	Non-Executive Chairman
Denning Chong	Managing Director and Chief Executive Officer
Andrew Just	Non-Executive Director

Other key management personnel

The following persons also had the authority and responsibility for planning, directing and controlling the major activities of the Group, directly or indirectly, during the financial year:

Martina Mariano	Chief Operating Officer
Paige Taylor	Chief Commercial Officer (appointed 15 September 2025)

Compensation

The aggregate compensation made to Directors and other members of key management personnel of the Group is set out below:

	30 June 2026 $	30 June 2025 $
Short-term employee benefits	1,102,558	865,509
Post-employment benefits	76,574	74,160
Share-based payments	1,172,143	2,408,918
	2,351,275	3,348,587

Note 22. Key management personnel disclosures (continued)

Performance rights
On 8 August 2025, Ms Martina Mariano, exercised 500,000 performance rights into ordinary shares. These rights were subject to vesting conditions based on share price performance and continuous employment.

Note 23. Related party transactions

Parent entity
Singular Health Group Limited is the ultimate Australian parent entity.

Subsidiaries
Interests in subsidiaries are set out in **note 27**.

Key management personnel
Disclosures relating to key management personnel are set out in **note 22** and the remuneration report included in the Directors' report.

Transactions with related parties
James Chong and Co Pty Ltd, a company associated with Denning Chong, received $5,309 excluding GST in fees (30 June 2025: $9,045) during the year for legal and marketing consulting provided to the Company, with $nil payable as at 30 June 2026.

Receivable from and payable to related parties
There were no trade receivables from or trade payables to related parties at the current and previous reporting date.

Loans to/from related parties
There were no loans to or from related parties at the current and previous reporting date.

Terms and conditions
All transactions were made on normal commercial terms and conditions and at market rates.

Note 24. Remuneration of auditors

During the financial year the following fees were paid or payable for services provided by Pitcher Partners Perth, the auditor of the Company:

	30 June 2026 $	30 June 2025 $
Audit services - Pitcher Partners Perth (30 June 2025:)		
Audit or review of the financial statements	48,128	51,995
Other services - Pitcher Partners Perth		
Preparation of the tax return and tax consolidation	11,000	45,045
US and Singapore tax advice	9,499	-
	20,499	45,045
	68,627	97,040

Note 25. Commitments and contingent liabilities

There are no contingent liabilities or commitments at 30 June 2026 and 30 June 2025.

Note 26. Parent entity information

Statement of profit or loss and other comprehensive income

	30 June 2026 $	30 June 2025 $
Loss after income tax	(7,129,606)	(2,972,222)
Total Comprehensive loss	(7,129,606)	(2,972,222)

Statement of financial position

	30 June 2026 $	30 June 2025 $
Total current assets	10,084,271	13,419,429
Total non-current assets	154,012	142,797
Total assets	10,238,283	13,562,226
Total current liabilities	(373,644)	(465,673)
Total non-current liabilities	(93,866)	-
	(467,510)	(465,673)
Issued capital	32,656,206	29,919,436
Share-based payment reserve	8,093,352	7,057,212
Accumulated losses	(31,007,536)	(23,877,930)
	9,742,022	13,098,718

Guarantees entered into by the parent entity in relation to the debts of its subsidiaries
The parent entity had no guarantees in relation to the debts of its subsidiaries as at 30 June 2026 and 30 June 2025.

Contingent liabilities
The parent entity had no contingent liabilities as at 30 June 2026 and 30 June 2025.

Material accounting policy information
The accounting policies of the parent entity are consistent with those of the Group, as disclosed in note 2, except for the following:
- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.
- Investments in associates are accounted for at cost, less any impairment, in the parent entity.
- Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.

Note 27. Interests in subsidiaries

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in **note 2**:

		Ownership interest	
Name	**Principal place of business / Country of incorporation**	**30 June 2026 %**	**30 June 2025 %**
Singular Health Pty Ltd	Australia	100%	100%
Singular Health Pte Ltd	Singapore	100%	100%
Singular 3DiCom Solutions USA Pty Ltd	Australia	100%	100%
Singular Health Group USA Pty Ltd[1]	Australia	100%	-
Singular Health Group USA LLC[2]	United States of America	100%	-
SHG Health Pte Ltd[3]	Singapore	100%	-

[1]The Company was incorporated on 4 July 2025 in Australia.
[2]The Company was incorporated on 7 August 2025 under the Delaware Limited Liability Company Act.
[3]The Company was incorporated on 12 June 2026 in Singapore.

Note 28. Events after the reporting period

No matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

Date	Details
30 July 2026	The Group's subsidiary Singular 3Dicom Solutions USA Pty Ltd (ACN 686 594 249) entered into and gave effect to a Stock Purchase Agreement to acquire 4,166,667 shares of common stock in Singular Imaging Solutions-US, Inc. ("SIS-US"), a Delaware corporation, from Marin & Sons Strategies, LLC for cash consideration of USD 175,000. Prior to the transaction, the Group held 4,285,710 shares, being 30% of SIS-US. Following the transaction the Group holds 8,452,377 shares, being approximately 60% of the issued and outstanding common stock, and has obtained control of SIS-US. The remaining 40% is held by PNS Singular, LLC (30%) and PNS PR MSO Holding, LLC (10%), both of which approved the transaction by written consent on 27 July 2026. From 30 July 2026 SIS-US will be consolidated as a controlled entity and a non-controlling interest will be recognised. The acquisition will be accounted for as a business combination achieved in stages, which requires the Group's previously held 30% interest to be remeasured to fair value at the acquisition date, with any resulting gain or loss recognised in profit or loss. At the date of this report the initial accounting for the acquisition is incomplete and the fair values of the identifiable assets acquired and liabilities assumed have not been finalised. Accordingly, the financial effect of the acquisition cannot yet be reliably estimated and will be disclosed in the Group's financial statements for the year ending 30 June 2027.

Singular Health Group Limited
Consolidated entity disclosure statement
As at 30 June 2026

Entity name	Entity Type	Place incorporated/formed	Ownership interest %	Australian or Foreign tax resident	Jurisdiction(s) for Foreign tax residency
Singular Health Group Limited	Body Corporate	Australia	-	Australian	N/A
Singular Health Pty Ltd	Body Corporate	Australia	100%	Australian	N/A
Singular Health Pte Ltd	Body Corporate	Singapore	100%	Australian	N/A
Singular 3DiCom Solutions USA Pty Ltd	Body Corporate	Australia	100%	Australian	N/A
Singular Health Group USA LLC	LLC	United States	100%	United States	N/A
SHG Health Pte Ltd	Body Corporate	Singapore	100%	Singapore	N/A
Singular Health Group USA Pty Ltd	Body Corporate	Australia	100%	Australian	N/A

Singular Health Group Limited (the "head entity") and its wholly owned eligible subsidiaries intend to form a tax consolidated group from 1 July 2024.

Key assumptions and judgements

Determination of Tax residency

Section 295 (3A) of the *Corporation Acts 2001* requires that the tax residency of each entity which is included in the Consolidated Entity Disclosure Statement (CEDS) be disclosed. For the purposes of this section, an entity is an Australian resident at the end of a financial year if the entity is:

(a) an Australian resident (within the meaning of the Income Tax Assessment Act 1997) at that time; or
(b) a partnership, with at least one partner being an Australian resident (within the meaning of the Income Tax Assessment Act 1997) at that time; or
(c) a resident trust estate (within the meaning of Division 6 of Part III of the Income Tax Assessment Act 1936) in relation to the year of income (within the meaning of that Act) that corresponds to the financial year.

The determination of tax residency involves judgment as the determination of tax residency is highly fact dependent and there are currently several different interpretations that could be adopted, and which could give rise to a different conclusion on residency.

In determining tax residency, the consolidated entity has applied the following interpretations:

• **Australian tax residency**
The consolidated entity has applied current legislation and judicial precedent, including having regard to the Commissioner of Taxation's public guidance in Tax Ruling TR 2018/5.

• **Foreign tax residency**
The consolidated entity has applied current legislation and where available judicial precedent in the determination of foreign tax residency. Where necessary, the consolidated entity has used independent tax advisers in foreign jurisdictions to assist in its determination of tax residency to ensure applicable foreign tax legislation has been complied with.

Singular Health Group Limited
Directors' declaration
30 June 2026

In the Directors' opinion:

- the attached financial statements and notes comply with the *Corporations Act 2001*, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;

- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in **note 2** to the financial statements;

- the attached financial statements and notes give a true and fair view of the Group's financial position as at 30 June 2026 and of its performance for the financial year ended on that date;

- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and

- the information disclosed in the attached consolidated entity disclosure statement is true and correct.

The Directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of Directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the Directors

____
Denning Chong
Managing Director

28 August 2026

PITCHER PARTNERS

SINGULAR HEALTH GROUP LIMITED
58 639 242 765

INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF
SINGULAR HEALTH GROUP LIMITED

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Singular Health Group Limited ("the Company") and its controlled entities ("the Group"), which comprises the consolidated statement of financial position as at 30 June 2026, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial statements including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

(a) giving a true and fair view of the Group's financial position as at 30 June 2026 and of its financial performance for the year then ended; and
(b) complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* issued by the Accounting Professional and Ethical Standards Board ("the Code") that are relevant to audits of the financial report of public interest entities in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key Audit Matter	**How our audit addressed the key audit matter**
Recognition of revenue Refer to Note 3, Note 4 and Note 5 to the financial report.	
For the year ended 30 June 2026, the Group had revenue of $1,376,819 from contracts with customers for its 3Dicom licenses activities. The determination of revenue recognition requires Management judgements in accounting for revenue accordance with the Group's identified performance obligations as part of the transaction, as required under *AASB 15 Revenue from contracts with customers* ("AASB 15"). In addition to the above, the Group had revenue of $51,412 from stripe sales, for which the performance obligations are satisfied at a point in time, being when the transaction takes place.	Our procedures included, amongst others: Understanding and evaluating the design and implementation of the relevant controls associated with the treatment of revenue, contract assets, and contract fulfillment costs, including, but not limited to, those relating to identification of performance obligations, discounts, incentives and rebates. Reviewing significant new contracts to understand their terms and conditions, including specified performance obligations included within and whether Management's assessment for recognition of revenue, contract assets, and contract fulfilment costs under these contract terms, is in accordance with AASB 15. Assessing the entitlement and recoverability for a sample of transactions within contract assets, evaluating their consistency and the basis of Management's approach for determining amounts recognised, understanding and corroborating key assumptions made, and recalculating contract assets recognised. Testing a sample of transactions by sighting evidence of signed contracts, related invoices and comparing the revenue, contract asset, and contract fulfilment cost amount recognised to the timing of when the Group satisfies performance obligations associated with the transaction in accordance with AASB 15. Testing a sample of stripe sale transactions by sighting supporting documentation and agreeing that the amount recognised in revenue is in-line with the amount received in the bank. Considering the adequacy of the disclosures included within Note 3, Note 4 and Note 5 of the financial report.
Share-based payments Refer to Note 9 to the financial report.	
During the year ended 30 June 2026, share-based payments of $2,089,670 have been recorded.	Our procedures included, amongst others:

SINGULAR HEALTH GROUP LIMITED
58 639 242 765

INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF
SINGULAR HEALTH GROUP LIMITED

Under Australian Accounting Standards, equity settled share based payments are measured at fair value of the services received, or if not reliably measurable, the fair value of the equity instruments granted on the measurement date taking into consideration the probability of the vesting conditions (if any) attached. This amount is recognised as an expense either immediately if there are no vesting conditions, or over the vesting period if there are vesting conditions. In calculating the fair value there are a number of judgements management must make, including but not limited to: • estimating the likelihood that the equity instruments will vest; • estimating expected future share price volatility; • expected dividend yield; and • risk-free rate of interest. Due to the significance of the share-based payment payments to the Group's financial report and the level of judgment involved in determining the valuation of the share-based payments, we consider the Group's calculation of the share-based payment expense to be a key audit matter.	Obtaining an understanding of design and implementation of the relevant controls associated with the preparation of the valuation model used to assess the fair value of share-based payments, including those relating to volatility of the underlying security and the appropriateness of the model used for valuation. Assessing the validity of shares and share options issued by verifying that the required shareholder approval was obtained prior to their issuance. Critically evaluating and challenging the methodology and assumptions of management in their preparation of valuation model, including management's assessment of likelihood of vesting, agreeing inputs to internal and external sources of information as appropriate. Assessing the competence and experience of the external valuation experts contracted by the Group to determine if we can place reliance on their valuations performed. Assessing the Group's accounting policy as set out within Note 2 for compliance with the requirements of AASB 2 *Share-based Payment*. Assessing the adequacy of the disclosures included within Note 8 of the financial report for compliance with the requirements of AASB 2.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2026, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Report
The directors of the Company are responsible for the preparation of:

a) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001*; and
b) the consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001*; and

for such internal control as the directors determine is necessary to enable the preparation of:
(i) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
(ii) the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the financial report. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial report of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 15 to 25 of the directors' report for the year ended 30 June 2026. In our opinion, the Remuneration Report of Singular Health Group Limited, for the year ended 30 June 2026, complies with section 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

Pitcher Partners BA&A PTY LTD

PITCHER PARTNERS BA&A PTY LTD

Paul Mulligan

PAUL MULLIGAN
Executive Director
Perth, 28 August 2026

Corporate Governance Statement

This Corporate Governance Statement is current as at 30 June 2026 and applies to the Consolidated Entity, consisting of Singular Health Group Ltd and its subsidiaries, together referred to as **Singular Health** or the **Group**. This Corporate Governance Statement has been approved by the Board of Singular Health.

The Board of Directors of Singular Health is responsible for the corporate governance of the Group. The Board guides and monitors the business and affairs of Group on behalf of the shareholders by whom they are elected and to whom they are accountable.

This Corporate Governance Statement discloses the extent to which the Group has, during the financial year ending 30 June 2026, followed the recommendations set by the ASX Corporate Governance Council in its publication Corporate Governance Principles and Recommendations (Recommendations). The Recommendations are not mandatory, but where the Recommendations have not been followed for any part of the reporting period, reasons are provided in this Statement, together with an explanation of any alternative governance practices adopted.

Information on corporate governance is available on the Company's website at https://singular.health/corporate- governance/.

Singular Health Group Limited
Shareholder information
30 June 2026

Additional information required by the ASX Limited Listing Rules not disclosed elsewhere in this Annual Report is set out below.

Shareholdings

The issued capital of the Company as at 25 August 2026 is 326,091,299 ordinary fully paid shares (inclusive of shares subject to voluntary escrow, set out in detail over page), 10,000,000 performance rights, and 76,752,772 unlisted options (details below).

All issued ordinary fully paid shares carry one vote per share.

Ordinary Shares

Shares Range	Holders	Units	%
above 0 up to and including 1,000	163	96,435	0.03
above 1,000 up to and including 5,000	635	1,730,126	0.53
above 5,000 up to and including 10,000	269	2,191,002	0.67
above 10,000 up to and including 100,000	670	24,799,176	7.61
above 100,000	310	297,274,560	91.16
Totals	**2,047**	**326,091,299**	**100.00**

Unmarketable parcels

There were 521 holders of less than a marketable parcel of ordinary shares, amounting to 0.23% of issued capital.

Top 20 Shareholders as at 25 August 2026

The names of the twenty largest security holders of quoted equity securities are listed below:

Name	Number held	% of total shares issued
MARIN & SONS STRATEGIES LLC	20,618,407	6.37
MR GUOSHENG CHEN	14,239,395	4.40
J P MORGAN NOMINEES AUSTRALIA PTY LIMITED	10,879,178	3.36
MANOLEV SUPERANNUATION PTY LTD <MANOLEV SUPER FUND A/C >	9,198,821	2.84
KLOSTERS HOLDINGS PTY LTD <MILBON HOLDINGS A/C >	8,400,000	2.59
NETWEALTH INVESTMENTS LIMITED <WRAP SERVICES A/C >	8,298,339	2.56
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	7,297,413	2.25
MARIN & SONS INC	7,285,416	2.25
MS CHONG LING DIAMOND CHEONG	7,065,754	2.18
MR ILIA JIVKOV MANOLEV	6,763,484	2.09
JCC HEALTH PTY LTD THE JDE MEDVR A/C	6,640,869	2.05
GAJA ENTERPRISES LTD	5,984,127	1.85
JDE CAPITAL PTY LTD <JDE CAPITAL A/C >	5,318,182	1.64
JDE CAPITAL PTY LTD <JDE CAPITAL A/C >	5,167,706	1.60
THREE BEARS MANAGEMENT PTY LTD <RICHARDSON LOW FAMILY A/C>	4,274,177	1.32
MS TZE HUA GOH	4,215,265	1.30
THREE BEARS MANAGEMENT PTY LTD <RICHARDSON LOW FAMILY A/C>	3,375,000	1.04
MR ZEYA WANG	3,350,000	1.03
CITICORP NOMINEES PTY LIMITED	3,176,416	0.98
MR QINGYUAN ZHANG	3,173,902	0.98
Total Top 20	**144,721,851**	**44.68**
Balance other holders	**181,369,448**	**55.32**

Singular Health Group Limited
Shareholder information
30 June 2026

Substantial holders

Substantial holders in the Company are set out below:

	Number held	% of total shares issued
Marin and Sons Strategies LLC	20,618,407	6.37
Denning Chong	17,429,719	5.38

Restricted securities subject to voluntary escrow

Class	Expiry date	Number of shares
SHGESC29 - VOLUNTARY ESCROWED SHARES	19/01/2027	1,720,000

Unquoted equity securities

There are 10,000,000 performance rights and 76,752,772 unlisted options over shares in the Company as at 28 August 2026 as follows:

	Number on issue	Number of holders
UNLISTED OPTIONS @ $0.08 EXP 08/12/2027	17,562,500	7
UNLISTED OPTIONS @ $0.10 EXP 09/02/2027	7,727,272	3
UNLISTED OPTIONS @ $0.15 EXP 25/07/2027	3,138,000	8
UNLISTED OPTIONS @ $0.15 EXP 28/11/2027	9,000,000	5
UNLISTED OPTIONS @ $0.15 EXP 19/02/2028	6,325,000	7
UNLISTED OPTIONS @ $0.25 EXP 15/04/2028	2,000,000	2
UNLISTED OPTIONS @ $0.25 EXP 15/10/2028	5,000,000	1
UNLISTED OPTIONS @ $0.25 EXP 15/04/2029	10,000,000	1
UNLISTED OPTIONS @ $0.55 EXP 26/06/2028	10,000,000	5
UNLISTED OPTIONS @ $0.55 EXP 30/11/2029	6,000,000	1
PERFORMANCE RIGHTS EXP 30/06/2028	10,000,000	2

Holders of Unlisted Securities over 20%

17,562,500 UNLISTED OPTIONS @ $0.08 EXP 08/12/2027 - 7 holders
Holders with more than 20%

Name	Holding	Percentage
JDE Capital	10,000,000	56.94

7,727,272 UNLISTED OPTIONS @ $0.10 EXP 09/02/2027 - 3 holders
Holders with more than 20%

Name	Holding	Percentage
MARIN AND SONS STRATEGIES LLC	6,818,181	88.24

3,138,000 UNLISTED OPTIONS @ $0.15 EXP 25/07/2027 - 8 holders
Holders with more than 20%

Name	Holding	Percentage
PARETO NOMINEES PTY LTD	900,000	28.68
PHILUCHNA PTY LTD	850,000	27.09
SANCERRE HOLDINGS PTY LTD	900,000	28.68
	2,650,000	84.45

9,000,000 UNLISTED OPTIONS @ $0.15 EXP 28/11/2027 - 5 holders
Holders with more than 20%

Name	Holding	Percentage
BLACK CREEK PTY LTD	1,800,000	20.00
KLOSTERS HOLDINGS PTY LTD	1,800,000	20.00
RAFTUS INVESTMENTS PTY LTD	1,800,000	20.00
THE NESTLENOOK PTY LTD	1,800,000	20.00
ZERRIN INVESTMENTS PTY LTD	1,800,000	20.00
	9,000,000	100.00

6,325,000 UNLISTED OPTIONS @ $0.15 EXP 19/02/2028 - 7 holders
Holders with more than 20%

Name	Holding	Percentage
VIAVAN PTY LTD	1,500,000	23.72
SHIRLEY STRAFACE	1,500,000	23.72
	3,000,000	47.44

2,000,000 UNLISTED OPTIONS @ $0.25 EXP 15/04/2028 - 2 holders
Holders with more than 20%

Name	Holding	Percentage
ANDREW JUST	1,000,000	50.00
HOWARD DIGBY	1,000,000	50.00
	2,000,000	100.00

5,000,000 UNLISTED OPTIONS @ $0.25 EXP 15/10/2028 - 1 holder
Holders with more than 20%

Name	Holding	Percentage
TREE BEARS MANAGEMENT PTY LTD	5,000,000	100.00

10,000,000 UNLISTED OPTIONS @ $0.25 EXP 15/04/2029 - 1 holder
Holders with more than 20%

Name	Holding	Percentage
MAXWELL STANLEY CAPITAL PTY LTD	10,000,000	100.00

10,000,000 UNLISTED OPTIONS @ $0.55 EXP 26/06/2028 - 5 holders
Holders with more than 20%

Name	Holding	Percentage
BLACK CREEK PTY LTD	2,000,000	20.00
KLOSTERS HOLDINGS PTY LTD	2,000,000	20.00
RAFTUS INVESTMENTS PTY LTD	2,000,000	20.00
THE NESTLENOOK PTY LTD	2,000,000	20.00
ZERRIN INVESTMENTS PTY LTD	2,000,000	20.00
	10,000,000	100.00

6,000,000 UNLISTED OPTIONS @ $0.55 EXP 30/11/2029 - 1 holder
Holders with more than 20%

Name	Holding	Percentage
MAXWELL STANLEY CAPITAL PTY LTD	6,000,000	100.00

On-market buyback
There is currently no on-market buyback program for any of Singular Health Group Limited’s listed securities.

Group cash and assets
In accordance with Listing Rule 4.10.19, the Group confirms that it has been using the cash and assets it had acquired at the time of admission and for the year ended 30 June 2026 in a way that is consistent with its business objective and strategy.